Cancer evidence library

Prostate Cancer

PubMed-indexed evidence for localized, advanced, metastatic, and treatment-resistant prostate cancer.

PubMed only Research ranked Conflicts shown Data downloadable

Living evidence synopsis

What the current PubMed collection shows.

Alexandria currently organizes 869 non-retracted PubMed-indexed records for Prostate Cancer. The structured collection includes 11 guideline or consensus records, 118 evidence syntheses/systematic reviews/meta-analyses, and 95 randomized or phase III studies. 369 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 594 of 869 included records.

Engine 0.3.2 Snapshot v11 Updated 2026-10-03 Download source data · CSV

PubMed records869Non-retracted records included

Last 24 months369Records found by the recent-research search

High-priority evidence213Syntheses, reviews, randomized and phase III studies

Effect estimates359Machine-readable values extracted from abstracts

COI statements68.4%Coverage within PubMed records

Funding records192PMIDs with grant/funding metadata

Evidence data

Research landscape

Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.

Publication activity

Records by publication year

Latest 12 represented years

2013

2016

2017

2019

2020

2021

2022

2023

2024

2025

746

2026

2027

Evidence composition

Study designs

Other or unclassified417

Preclinical/laboratory122

Randomized trials80

Meta-analyses75

Systematic reviews43

Phase II trials29

Cohort studies20

Prospective cohorts16

Phase III trials15

Observational studies14

Transparency

Conflict-of-interest reporting

Reported no conflicts293

Not reported in PubMed record275

COI statement present222

Declared financial/industry relationship79

Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.

Abstract result signals

Extracted result direction

Not extractable from abstract764

Neutral/null signal49

Supportive signal29

Harm signal23

Mixed signal4

Reported outcomes

Numerical results extracted from PubMed abstracts

Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.

Non-pooled ratio measures

Hazard, risk, and odds ratios reported in abstracts

Reference = 1.0

0.250.51.02.04.0

not_reported Hazard Ratio · PMID 39613566 · 2026

2.10

not_reported Hazard Ratio · PMID 39613566 · 2026

0.60 95% CI 0.10–2.40

not_reported Hazard Ratio · PMID 39613566 · 2026

2.00 95% CI 1.10–3.64

not_reported Odds Ratio · PMID 41033927 · 2026

160.00

not_reported Hazard Ratio · PMID 41033927 · 2026

1.90

not_reported Hazard Ratio · PMID 41494929 · 2026

1.03 95% CI 0.75–1.41

not_reported Odds Ratio · PMID 41548387 · 2026

5.00

not_reported Odds Ratio · PMID 41548387 · 2026

5.00

not_reported Odds Ratio · PMID 41570179 · 2026

120.00

not_reported Odds Ratio · PMID 41891526 · 2026

1.29

not_reported Odds Ratio · PMID 41891526 · 2026

1.67

not_reported Odds Ratio · PMID 41891526 · 2026

3.10

not_reported Hazard Ratio · PMID 41891526 · 2026

1.00

not_reported Hazard Ratio · PMID 41891526 · 2026

1.16

View extracted numerical results 60

Publication	Outcome	Measure	Reported value	Source
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.European urology oncology · 2026	not_reported	Hazard Ratio	2.1 p = 0.01	PMID 39613566
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.European urology oncology · 2026	not_reported	Hazard Ratio	0.6 95% CI 0.1–2.4 p = 0.45	PMID 39613566
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.European urology oncology · 2026	not_reported	Hazard Ratio	2.0 95% CI 1.1–3.64 p = 0.007	PMID 39613566
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.European urology oncology · 2026	not_reported	Odds Ratio	160.0	PMID 41033927
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.European urology oncology · 2026	adverse events	Percentage Comparison	65.4percent vs 30.2percent	PMID 41033927
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.European urology oncology · 2026	not_reported	Hazard Ratio	1.9 p = 0.02	PMID 41033927
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.European urology · 2026	not_reported	Hazard Ratio	1.03 95% CI 0.75–1.41 p = 0.87	PMID 41494929
Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	not_reported	Odds Ratio	5.0	PMID 41548387
Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	not_reported	Odds Ratio	5.0	PMID 41548387
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial.The Prostate · 2026	recurrence	Percentage Comparison	1.5percent vs 9.0percent p = 0.006	PMID 41570179
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial.The Prostate · 2026	recurrence	Percentage Comparison	0.0percent vs 5.7percent p = 0.006	PMID 41570179
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial.The Prostate · 2026	not_reported	Odds Ratio	120.0	PMID 41570179
Age-related patterns in prostate cancer: epidemiology, pathology, treatment, and survival.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Odds Ratio	1.29 p < 0.001	PMID 41891526
Age-related patterns in prostate cancer: epidemiology, pathology, treatment, and survival.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Odds Ratio	1.67 p < 0.001	PMID 41891526
Age-related patterns in prostate cancer: epidemiology, pathology, treatment, and survival.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Odds Ratio	3.1 p < 0.001	PMID 41891526
Age-related patterns in prostate cancer: epidemiology, pathology, treatment, and survival.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Hazard Ratio	1.0 p = 0.872	PMID 41891526
Age-related patterns in prostate cancer: epidemiology, pathology, treatment, and survival.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Hazard Ratio	1.16 p = 0.872	PMID 41891526
Age-related patterns in prostate cancer: epidemiology, pathology, treatment, and survival.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Hazard Ratio	1.72 p = 0.872	PMID 41891526
Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).European urology · 2026	not_reported	Hazard Ratio	64.0	PMID 41904043
Causal association and shared mechanisms between Graves' disease and prostate cancer: insights from Mendelian randomization, machine learning, and comprehensive bioinformatics.The aging male : the official journal of the International Society for the Study of the Aging Male · 2026	not_reported	Odds Ratio	0.997 95% CI 0.996–0.999 p = 0.004	PMID 42454507
Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone.Adipocyte · 2026	not_reported	Odds Ratio	1.523 95% CI 1.252–1.853 p < 0.001	PMID 42231146
Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.BJU international · 2026	not_reported	Hazard Ratio	0.5	PMID 42117295
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	0.91 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	0.97 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	1.29 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	0.98 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	1.03 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	0.94 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	1.02 P = 0.5	PMID 42436100
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.Urologic oncology · 2026	adverse events	Odds Ratio	1.06 P = 0.5	PMID 42436100
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.International journal of urology : official journal of the Japanese Urological Association · 2026	survival	Hazard Ratio	1.96 95% CI 1.02–3.77 p = 0.0426	PMID 42161369
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.International journal of urology : official journal of the Japanese Urological Association · 2026	not_reported	Hazard Ratio	3.27 95% CI 1.08–9.89 p = 0.0354	PMID 42161369
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.Prostate cancer and prostatic diseases · 2026	not_reported	Hazard Ratio	0.27	PMID 41366131
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.Prostate cancer and prostatic diseases · 2026	not_reported	Hazard Ratio	0.52	PMID 41366131
Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026	not_reported	Odds Ratio	1.17 P = 0.009	PMID 41298852
Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026	not_reported	Odds Ratio	1.2 P = 0.009	PMID 41298852
Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026	not_reported	Odds Ratio	0.79 P = 0.009	PMID 41298852
Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026	not_reported	Odds Ratio	0.94 P = 0.009	PMID 41298852
Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.International journal of cancer · 2026	adverse events	Risk Ratio	1.42	PMID 42017392
Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.International journal of cancer · 2026	adverse events	Risk Ratio	2.56	PMID 42017392

Research transparency

Funding and conflicts of interest

Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.

COI statement coverage68.4%275 records have no COI statement exposed in PubMed.

Funding metadata coverage22.1%Coverage indicates whether grant/funding metadata was present, not independence or study quality.

Most frequently reported funding agencies

NCI NIH HHS189

NIH HHS44

NIGMS NIH HHS19

National Cancer Institute (NCI)17

NHLBI NIH HHS12

National Natural Science Foundation of China11

National Natural Science Foundation of China (National Science Foundation of China)9

Prostate Cancer Foundation (PCF)8

View records with declared financial or industry relationships 12

Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature.

Declarations. Conflict of Interest: BH, AH, JC, DR, MR, and SD are employees of Pfizer and may hold stocks/stock options for Pfizer, which sponsored this review and the development of this publication. VW is an employee of RTI Health Solutions and is an Editorial Board Member of The Patient. She was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. SC has previously been a consultant for Pfizer. NA reports no honoraria related to this work and reports travel support from Pfizer, Exelixis, and Johnson & Johnson to attend meetings of the respective pharmaceutical companies. Research funding has been provided to NA’s institution by the following: Arnivas, Astellas, Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Data Availability Statement: The data that support the findings of this literature review are available in the article itself or its supporting information. Authors’ Contributions: All authors made a significant contribution to this work, whether that is in the conception, study design, execution, analysis, or interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

PMID 41817839 · 2026

Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis.

Declaration of competing interest Sangeet Ghai has received research funding and honorarium for a presentation from Exact Imaging. Dr. Hugo Lavigueur-Blouin reports consulting fees and advisory board participation for Exact Imaging, Civco Medical, and Knight Therapeutics. Sven Löffeler reports honoraria for presentations from Ipsen and Pfizer; Chairman of the Scandinavian Prostate Cancer Group (SPCG) and the Norwegian specialty board of urology; Member of the Norwegian guidelines committee on prostate cancer; Vestfold Hospital Trust serves as a site for case visits for Exact Imaging and EDAP. Giovanni Lughezzani has received travel support from AbMedica and EDAP TMS and speaker fee from EDAP TMS. Dr. Miles Mannas reports honoraria from AbbVie, Bayer, and TerSera; consulting fees from AbbVie, Bayer, Hexamer Therapeutics, Initio, Johnson & Johnson, and TerSera; and research funding from TerSera. Xiaosong Meng has served as a consultant for Profound Medical, AngioDynamics, and Exact Imaging, and has received clinical trial support from Profound Medical and AngioDynamics. Bruno Nahar reports consultant role or EDAP/FocalOne and Board advisor for Visano Theranostics. Tiago Rodrigues reports proctor and advisor role for Procept Biorobotics, FocalOne, Exact Image Julian Struck reports receiving speaker and travel grants from Johnson & Johnson, Novartis, Roche, Eisai, Solution Akademie GmbH, Apogepha, Merck; serving on advisory boards for Farco Pharma, Dr. Pfleger, and Boston Scientific; and holding investments in DHC Digital Health Center GmbH. Adam Kinnaird reports grant funding from Terry Fox Research Institute, Marathon of Hope Cancer Centers Network, Movember, Procure, Canadian Urology Association, Government of Alberta, University of Alberta, Genome Canada, Alberta Health Services, University Hospital Foundation, Bird Dogs, Alberta Cancer Foundation, and Exact Imaging; Honoraria from Boston Scientific and Bayer. No other disclosures were reported.

PMID 42476253 · 2026

Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Amar Kishan, MD reports financial support was provided by National Institutes of Health. Amar Kishan, MD reports financial support was provided by US Department of Defense. Amar Kishan reports a relationship with ViewRay Systems Inc that includes: funding grants. Amar Kishan reports a relationship with Novartis that includes: consulting or advisory and funding grants. Amar Kishan reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Amar Kishan reports a relationship with Lantheus Medical Imaging Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Amar Kishan reports a relationship with Varian Medical Systems Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Amar Kishan reports a relationship with Boston Scientific Corporation that includes: speaking and lecture fees. Amar Kishan reports a relationship with MiraDx that includes: equity or stocks. Amar Kishan reports a relationship with AlethianAI that includes: equity or stocks. Luca Valle reports a relationship with Bristol-Myers Squibb Foundation Inc that includes: funding grants. Luca Valle reports a relationship with Parker Institute for Cancer Immunotherapy that includes: funding grants. Luca Valle reports a relationship with ASCO Winn CILA Award that includes: funding grants. Luca Valle reports a relationship with US Department of Veterans Affairs that includes: funding grants. Luca Valle reports a relationship with The Dedham Group LLC that includes: consulting or advisory. Luca Valle reports a relationship with Health Advances LLC that includes: consulting or advisory. Holly Wilhalme reports a relationship with Lantheus Medical Imaging Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PMID 42435817 · 2026

Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.

Declarations. Conflict of interest: JHP received honoraria from Ferring, and Sumitomo Pharma, consulting/advising fees from Ferring, and Sumitomo Pharma, research funding from Ferring, and speaker fees from Ferring, and Sumitomo Pharma. MKD received speaking and consulting honoraria from Ferring. TN received research/educational funds from Abbvie, Astellas, Bayer, Janssen, Amgen, Sanofi, Astrazeneca, TerSera, and Tolmar, and honoraria from Abbvie, Astellas, Bayer, Janssen, Amgen, Sanofi, Astrazeneca, TerSera, Knight Therapeutics, Paladin, Watson, Merck, Ferring, and Tolmar. JBS received research grants from Biotronik, Sanofi, Pfizer, and Attralus, speaker fees from AstraZeneca, Boehringer-Ingelheim, Novartis, Abbott, Bayer, Sanofi, Biotronik, CircleCVI, Takeda, and Amicus, and advising fees from BMS, Sanofi, and Attralus. ED received bursary awards from Fonds de Recherche en Sante, and research grants for investigator-initiated projects from Roche Diagnostics, Diagnoptics, and Abbott Laboratories. DL received consulting fees from Abbvie, Novartis, Antev, Ipsen, Bayer, Boston Scientific, and Xfacto, speaker fees from Ferring, and Pfizer, advising fees from Janssen, Jazz Pharmaceuticals, and Sanofi, research support from Novartis, and Tolmar, and is on the steering committee for Myovant. No other authors have conflicts of interest to disclose relevant to this manuscript. Ethical approval: The authors confirm that this study was approved by the appropriate institutional and/or national research ethics committee (CTO-0743 in Ontario, Canada) and certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

PMID 41807888 · 2026

MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes.

No author has received employment, consultancy fees, stock ownership, honoraria, paid expert testimony, patent applications, grants, or any other form of funding from any organisation that could be perceived as influencing the work reported in this manuscript. The study received no external funding.

PMID 42571475 · 2026

Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer.

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Daniel J. George reports receiving research funding from Bayer. Karim Fizazi reports a consulting or advisory role on behalf of institution for Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Clovis Oncology, ESSA, Janssen Oncology, Novartis, Orion, Pfizer, and Sanofi; travel/accommodation/expenses to institution from AstraZeneca, Janssen, and MSD; and honoraria to institution from Astellas Pharma, Bayer, Janssen, and Sanofi. Alicia K. Morgans reports a consulting or advisory role for Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, BMS, Curium, Exact Sciences, Exelixis, Janssen, Lantheus Medical Imaging, MacroGenics, Merck, Novartis, Pfizer, Sanofi, Sumitomo Pharma Oncology, Telix Pharmaceuticals, and Tolmar; honoraria from Advanced Accelerator Applications, Astellas Scientific and Medical Affairs, AstraZeneca, Bayer, Curium Pharma, Janssen, Janssen Oncology, Merck, Novartis, Pfizer, and Telix Pharmaceuticals; research funding from Astellas Scientific and Medical Affairs, Bayer, Janssen, Pfizer, and Seattle Genetics/Astellas; travel/accommodation/expenses from Bayer and Pfizer; and stock in Vertex. Hannah D. McManus reports a consulting or advisory role for Astellas Pharma, Bayer, Johnson and Johnson; honoraria from Astellas Pharma, Bayer, and Johnson and Johnson; research funding to institution from Novartis, and travel/accommodation/expenses from Astellas and Bayer. Yen Yen Yip was a full-time employee of Bayer at the time of the study. Shankar Srinivasan, Maxime Duflot, and Alexander Upton are full-time employees of Bayer. Fred Saad reports a consulting or advisory role for AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca/MedImmune, Bayer, Janssen Oncology, Knight Therapeutics, Myovant Sciences, Novartis, Pfizer, and Sanofi; honoraria from AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, BMS, Janssen Oncology, Knight Therapeutics, Merck, Myovant Sciences, Novartis, Pfizer, and Sanofi; and research funding to institution from Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, BMS, Janssen Oncology, Merck, Novartis, Pfizer, and Sanofi.

PMID 42617299 · 2026

Rethinking the PSMA-mediated tumor targeting of nanocarrier and potentiating co-delivery of PARP/EZH2 inhibitors for robust prostate cancer treatment.

Declaration of competing interest The authors have filed patent applications for some aspects of this work (No. 202610907630.X in China). The authors declare no other competing interests.

PMID 42492356 · 2027

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

Toni Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria past 5 years, ongoing or not, from: • Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Bicycle Therapeutics, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO and others), Xencor, outside the submitted work. • Institutional patents filed on molecular alterations and immunotherapy response/toxicity, rare genitourinary cancers, and ctDNA/liquids biopsies. • Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura Therapeutics, Primium, Abalytics, Faron Pharma. • Committees: NCCN, GU Steering Committee, ASCO (BOD 6-2024-, ESMO, ACCRU, KidneyCan. • Medical writing and editorial assistance support may have been funded by Communications companies in part. • Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. • The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. • T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. Jeremiah Wala reports the following: BullFrog AI Inc: Consulting fees and stock options for bioinformatics consulting. BullFrog AI is an AI-driven drug discovery company but has not worked with any prostate cancer or digital pathology images. Johann de Bono. JDB has served on advisory boards and received fees from many companies including Abbvie, Acai Therapeutics, Amgen, Amunix, Astellas, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Celcuity, Daiichi, Dark Blue Therapeutics, Duke Street Bio Limited, Dunad Therapeutics, Eikon Therapeutics, Endeavor Biomedicines INC, Genentech/Roche, GSK, Macrogenics, Merck Serono, MetaCurUm, Moma, Morphosys, Myricx, Novartis, Nurix Therapeutics, Nuvation Bio, Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs, One-Carbon Therapeutics Inc, Oncternal, Orion, Page Therapeutics, Peptone, Pfizer, Takeda, Tango Therapeutics, Tubulis GmbH, VIR Biotechnology. He is an employee of The ICR, which have received funding or other support for his research work from AstraZeneca, Crescendo, Immunic Therapeutics, MetaCurUm, Morphosys, Myricx, Nurix Therapeutics, Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs, Oncternal, Orion, Sanofi Aventis. The ICR have a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income). JDB was named as an inventor, with no financial interest for patent 8,822,438, submitted by Janssen that covers the use of abiraterone acetate with corticosteroids. He has been the CI/PI of many industry sponsored clinical trials. JDB is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Eliezer Van Allen reports the following: Advisory/Consulting: Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, TracerBio. Research support: Novartis, BMS, Sanofi, NextPoint. Equity: Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse, TracerDx. Travel reimbursement: None. Speaking Fees: TD Cowen. Patents: Institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation; intermittent legal consulting on patents for Foaley & Hoag. Editorial Boards: Science Advances

PMID 42113020 · 2026

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

Conflict of Interest Disclosures: Dr Zilli reported receiving grants from Varian Medical Systems and the Fondation pour les Recherches Médicales et Biologiques sur le Cancer during the conduct of the study; receiving honoraria/travel costs (institutional) from Janssen, Amgen, Ferring, Debiopharm, Bayer, Astellas, Telix, Accord, and Recordati; receiving research grants from Astellas, Rising Tide, Krebsforschung Schweiz, Ente Ospedaliero Cantonale - Oncology Institute of Southern Switzerland, and Fond'action contre le Cancer; and serving on advisory boards (institutional) for Janssen, Accord, Astellas, Ipsen, and Recordati. Dr Guckenberger reported receiving nonfinancial support from Siemens Healthineers outside the submitted work. Dr Giaj-Levra reported receiving personal fees from AstraZeneca outside the submitted work. Dr Mach reported being a minority shareholder and cofounder of Release Therapeutics outside the submitted work. Dr Scorsetti reported having a clinical trial agreement from Geneva University Hospital during the conduct of the study. Dr Mirabell reported receiving grants from Varian AG during the conduct of the study. No other disclosures were reported.

PMID 42313395 · 2026

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Declarations. Conflicts Of interest: KC, CG, RR, AF, SC, CB, MC, IF, AS, AP and JDB are all employees of The Institute of Cancer Research (ICR), which has a commercial interest in abiraterone, PARP inhibition in DNA repair–defective cancers, and PI3K/AKT pathway inhibitors (no personal income). The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing. AP has been the CI/PI of industry-sponsored clinical trials and has received honoraria from Boehringer Ingelheim. AS has received travel support from Sanofi, Roche/Genentech, and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research, CHARM Therapeutics, Ellipses Pharma, and Droia Ventures. JDB has served on advisory boards and received fees from many companies including Abbvie, Acai Therapeutics, Amgen, Amunix, Astellas Nordic, Bayer, Bioxcel Therapeutics, Celcuity, Crescendo, Daiichi, Dark Blue Therapeutics, Duke Street Bio Limited, Dunad Therapeutics, Endeavor Biomedicines INC, Genentech/Roche, GSK, Macrogenics, Merck Serono, MetaCurUm, Moma, Myricx, Novartis, Nurix Therapeutics, Nuvation Bio, One-Carbon Therapeutics Inc, Oncternal, Orion, Page Therapeutics, Pfizer, Takeda, Tango Therapeutics, Tubulis GmbH. He is an employee of The ICR, which have received funding or other support for his research work from AstraZeneca, Cellcentric, Crescendo, Daiichi, Immunic Therapeutics, MetaCurUm, Myricx, Nurix Therapeutics, Oncternal, Orion, Sanofi Aventis. JDB was named as an inventor, with no financial interest for patent 8,822,438, submitted by Janssen that covers the use of abiraterone acetate with corticosteroids. He has been the CI/PI of many industry sponsored clinical trials. SP received research funding from AstraZeneca, Ferring, Jannsen, Guardant Health and has consultancy in Astra Zeneca, Roche, Elsevier and Bayer. CY received consultancy fees from FARON Pharmaceuticals unrelated to this work. AA is a co-founder of and owns stock in OncoSense and MicThera. He has served as an advisor to IBSA Institut Biochimique, Relmada Therapeutics, MicThera, BIOREK, Debiopharm International, ONO Pharma UK. He is an employee of The Institute of Oncology Research (IOR) in Bellinzona (Switzerland), which have received funding for his research work from AlpENa Biosciences, Astellas Pharma, AstraZeneca, IBSA Institut Biochimique, Macomics, Novartis, Peptone, Sun Pharma Global, MGGM, NovaRock Biotherapeutics. He was named as an inventor, with no financial interest for patent US20200095314A1 and US11168134B2, that cover the use of an IL23 inhibitor for treating of prostate cancer. BC, MM, and AC are all employees of IOR.

PMID 42141162 · 2026

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer.

Competing interests: AM: Consulting or advisory role: Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, BMS, Bayer, Curium, Exact Sciences, Exelixis, Inc., Janssen, Lantheus Medical Imaging, Macrogenics, Merck, Novartis, Pfizer, Sanofi, Sumitomo Pharma, Telix Pharmaceuticals, Tolmar; Honoraria: Advanced Accelerator Applications, Astellas Scientific and Medical Affairs Inc., AstraZeneca, Bayer, Curium Pharma, Janssen, Janssen Oncology, Merck, Novartis, Pfizer, Telix Pharmaceuticals; Research funding: Astellas Scientific and Medical Affairs Inc., Bayer, Janssen, Pfizer, Seattle Genetics/Astellas; Travel, accommodations, expenses: Bayer, Pfizer; Stock and other ownership: Vertex. CJDW: Consulting fees: Janssen Oncology, Nanostics Inc, Precision Point Specialty LLC, SESEN Bio; Honoraria/travel: AbbVie, Astellas, Astra Zeneca, Bayer, EMD Serono, Haymarket Media, Healing and Cancer Foundation, Knight Therapeutics, Merck, Science & Medicine Canada, TerSera Canada, Tolmar Pharmaceuticals Canada; Research funding: Bayer, Knight Therapeutics, Tolmar Pharmaceuticals. SH: Employment: American Society for Clinical Oncology (ASCO); Honoraria: AVEO Oncology, Beigene, Bristol Myers Squibb, CG Oncology, Janssen, Sanofi. AJA: Consulting or advisory role: Astellas Scientific and Medical Affairs Inc, AstraZeneca, Bayer, Bristol-Myers Squibb, Epic Sciences, Exelixis, FORMA Therapeutics, GoodRx, IDEAYA Biosciences, Janssen, Merck, Myovant Sciences, Novartis, Pfizer; Research funding: Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), BeiGene (Inst), Bristol-Myers Squibb (Inst), Bristol-Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Dendreon (Inst), FORMA Therapeutics (Inst), Gilead Sciences (Inst), Janssen Oncology (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Roche/Genentech (Inst); Patents, royalties, other intellectual property: Circulating tumor cell novel capture technology (Inst); Travel, accommodations, expenses: Astellas Scientific and Medical Affairs Inc. PA: Employment: Bayer. MG: Employment: Bayer. FV: Employment: Bayer. MOG: Research funding: Bayer Vital, BMS, Intuitive Surgical; Consulting/advisory role: Astellas, AstraZeneca, Bayer Vital, BMS, Eisai, EUSA Pharma, Gilead, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Roche Pharma AG, Takeda.

PMID 41680329 · 2026

A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

A.D. Choudhury reports grants from NCI and the Department of Defense and nonfinancial support from Merck KGaA, Darmstadt, Germany, during the conduct of the study, as well as personal fees from Outcomes4Me, Bayer, Tolmar, Janssen/Johnson & Johnson, Pfizer, Astellas, Bayer, Daiichi Sankyo, Boundless Bio, Novartis, and Blue Earth; grants from Merck & Co. (Rahway, NJ), Bayer, Eli Lilly, and Pfizer; and nonfinancial support from Sumitomo Pharma America outside the submitted work. C. Zhong reports grants from the NCI during the conduct of the study. W. Xie reports grants from NCI during the conduct of the study, as well as personal fees from the Prostate Cancer Clinical Trials Consortium outside the submitted work. I.B. Riaz reports other from Eisai, Horizon CME, and MJH Life Sciences outside the submitted work. M. Parikh reports grants from NCI during the conduct of the study, as well as personal fees from Pfizer, Bristol Myers Squibb, Sanofi, Janssen, Lilly, Exelixis, Bicycle Therapeutics, Natera, and AstraZeneca; nonfinancial support from Gilead; and grants from Karyopharm outside the submitted work. D.J. Einstein reports grants from Bristol Myers Squibb, Cardiff, Novartis, Iovance and personal fees from Bayer, Johnson & Johnson, Nimbus, and Xilio outside the submitted work. E.R. Kessler reports other from J&J, Merck, Lilly, Astellas, HiberCell, and Pathos outside the submitted work. T. Mayer reports other from Rutgers Cancer Institute during the conduct of the study, as well as personal fees from Pfizer, Janssen/Johnson & Johnson, and AstraZeneca and other from Merck and Curium outside the submitted work. R.R. McKay reports that R.R. McKay is a consultant/advisor for Astellas Medivation, Ambrx, Arcus Biosciences, Artera, AstraZeneca, AVEO, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Dendreon, Eisai, Exelixis, Janssen, Lilly, Merck, NeoMorph, Novartis, Pfizer Inc., Sanofi, Seagen, Sorrento Therapeutics, Sumitomo Pharma America, Inc., Telix Pharmaceuticals, Tempus, and Vividion Therapeutics. A. Pace reports personal fees from CLASP Therapeutics outside the submitted work. K.W. Mouw reports personal fees from EMD Serono, Pfizer, UroGen, Natera, Astellas, Illudent Therapeutics, UpToDate, and OncLive and grants from Novo Ventures outside the submitted work. L. Chen reports grants from the NCI during the conduct of the study. V.A. Adalsteinsson reports a patent to MAESTRO (17/792,638) pending and licensed and that V.A. Adalsteinsson is a cofounder of and advisor to Amplifyer Bio. E.M. Van Allen reports personal fees from Tango Therapeutics, Monte Rosa Therapeutics, Manifold Bio, Enara Bio, Serinus Bio, Cellyrix, TracerBio, AtlasMed, and BioLucidate; grants and personal fees from Novartis; and grants from Bristol Myers Squibb and Janssen outside the submitted work, as well as Institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation, pending and issued. A. D’Andrea reports personal fees from AbbVie, Deerfield Management Company LP, OrbiMed Advisors LLC, and Schrödinger Inc. and other from Servier Bio-Innovation LLC, Brainstorm Cancer Therapeutics, Covant Therapeutics/Roivant, Impact Therapeutics, and Skyhawk Therapeutics Inc. outside the submitted work. G.I. Shapiro reports grants and personal fees from Merck KGaA/EMD Serono during the conduct of the study, as well as grants from Pfizer, Lilly, Artios, and Sumitomo and personal fees from Circle Pharmaceuticals, Schrödinger, ForRx Therapeutics, Concarlo Therapeutics, and MycRx outside the submitted work, and a patent to Dosage regimen for sapacitabine and seliciclib issued and a patent to Compositions and Methods for Predicting Response and Resistance to CDK4/6 inhibition issued. No disclosures were reported by the other authors.

PMID 42636061 · 2026

The Journal of urology · 2026

PURPOSE: The recommendations discussed on the early detection of prostate cancer provide a framework to facilitate clinical decision-making in the implementation of prostate cancer screening and follow-up. MATERIALS AND METHODS: The Early Detection of Prostate Cancer Guideline was reviewed in 2025 and updated through the AUA amendment process. This process involved reviewing and integrating newly published literature into the previously established Guideline. The methodologist updated the original Guideline search strategy to systematically search Ovid MEDLINE and Embase for new evidence published between November 2022 and December 2024. RESULTS: The Early Detection of Prostate Cancer Amendm…

PMID 41744286

Prostate cancer and prostatic diseases · PMID 41857380

Treatment Options Studied in the PubMed Collection

These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.

preliminary evidence

radiotherapy

69 linked PMIDs23299 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, quality of life, recurrence, adverse events, biochemical recurrence, progression-free survival, overall survival, response rate
Populations represented: general population; PSA; metastatic; PSA; metastatic; localized prostate cancer; localized; advanced
Mechanism: Couch shifts were calculated based on rigid registration targeting the CTV This method's ability to preserve both global and local anatomical features shows potential for improving tumor targeting, adaptive radiotherapy planning, and clinical decision-making

PMID 41435426 PMID 41437135 PMID 41254344 PMID 42795342 PMID 42732820 PMID 40664550 PMID 42435817 PMID 42810617

moderate-confidence evidence

radical prostatectomy

57 linked PMIDs18436 reported cumulative sample signal

Research status: mostly neutral
Outcomes represented: reported clinical outcomes, recurrence, quality of life, biochemical recurrence, progression-free survival, overall survival, adverse events, recurrence-free survival
Populations represented: general population; PSA; localized prostate cancer; localized; localized; metastatic; locally advanced; advanced; PSA
Mechanism: BACKGROUND: Androgen receptor signaling inhibition (ARPI) increases genomic instability of double-stranded DNA breaks, and co-inhibition of androgen receptor (AR) and poly(ADP-ribose) polymerase (PARP) induces synthetic lethality in multiple preclinical models Patients with > 10 PSMA-positive distant metastases continued apalutamide therapy, while those with ≤ 10 metastases underwent radical prostatectomy or radiotherapy, with stereotactic body radiotherapy targeting all remaining PSMA-positive lesions, if present

PMID 41857380 PMID 42671634 PMID 42821140 PMID 42391449 PMID 42628214 PMID 42802868 PMID 40721878 PMID 42506856

preliminary evidence

Prostate-Specific Antigen

42 linked PMIDs123366 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, response rate, progression-free survival, quality of life, recurrence, biochemical recurrence, objective response rate
Populations represented: PSA; general population; metastatic castration-resistant prostate cancer; metastatic; PSA; metastatic; PSA; locally advanced; advanced; PSA; metastatic
Mechanism: This phase I trial (NCT04249947) evaluated the safety and efficacy of P-PSMA-101, an autologous TSCM-rich, bone-tropic CAR T-cell therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castrate-resistant prostate carcinoma (mCRPC) 225Ac-PSMA-CY313 is a next-generation radioligand designed to reduce off-target salivary uptake while maintaining tumor-targeting efficacy

PMID 42275039 PMID 37264206 PMID 42686465 PMID 42735240 PMID 42616976 PMID 37865044 PMID 41588191 PMID 42765541

moderate-confidence evidence

androgen deprivation therapy

36 linked PMIDs14004 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, progression-free survival, recurrence, adverse events, mortality, quality of life, PSA response
Populations represented: general population; metastatic; advanced; PSA; metastatic; PSA; localized prostate cancer; localized
Mechanism: The interleukin-1 (IL-1) receptor antagonist (IL1RN), a key anti-inflammatory molecule, plays a significant role in suppressing IL-1-related immune and inflammatory responses Clinical correlations between IL1RN and CHRM4 expression in advanced PCa patients and neuroendocrine PCa organoid models highlight their potential as therapeutic targets

PMID 39547874 PMID 36382930 PMID 35085341 PMID 41807888 PMID 41718424 PMID 42758864 PMID 37945451 PMID 41817839

moderate-confidence evidence

Androgen Antagonists

23 linked PMIDs6451 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, recurrence, PSA response, progression-free survival, adverse events, pathological complete response, quality of life
Populations represented: general population; metastatic; metastatic; PSA; localized prostate cancer; high-risk localized prostate cancer; localized; PSA; homologous recombination repair; metastatic castration-resistant prostate cancer; metastatic; localized; locally advanced; advanced; metastatic
Mechanism: Patients with > 10 PSMA-positive distant metastases continued apalutamide therapy, while those with ≤ 10 metastases underwent radical prostatectomy or radiotherapy, with stereotactic body radiotherapy targeting all remaining PSMA-positive lesions, if present BACKGROUND: Androgen receptor signaling inhibition (ARPI) increases genomic instability of double-stranded DNA breaks, and co-inhibition of androgen receptor (AR) and poly(ADP-ribose) polymerase (PARP) induces synthetic lethality in multiple preclinical models

PMID 39547874 PMID 36382930 PMID 35085341 PMID 41807888 PMID 42258930 PMID 41718424 PMID 42252578 PMID 37945451

preliminary evidence

Antigens, Surface

19 linked PMIDs19683 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, progression-free survival, overall survival, biochemical recurrence, recurrence, radiographic progression-free survival, adverse events, objective response rate
Populations represented: general population; metastatic castration-resistant prostate cancer; metastatic; PSA; PSA; metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic castration-resistant prostate cancer; metastatic; metastatic castration-resistant prostate cancer; metastatic; previously treated; PSA
Mechanism: Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC This phase I trial (NCT04249947) evaluated the safety and efficacy of P-PSMA-101, an autologous TSCM-rich, bone-tropic CAR T-cell therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castrate-resistant prostate carcinoma (mCRPC)

PMID 42663310 PMID 41857380 PMID 42392697 PMID 42346249 PMID 42235186 PMID 42641497 PMID 42595485 PMID 41779004

preliminary evidence

Glutamate Carboxypeptidase II

18 linked PMIDs19604 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: progression-free survival, reported clinical outcomes, overall survival, biochemical recurrence, recurrence, radiographic progression-free survival, adverse events, objective response rate
Populations represented: metastatic castration-resistant prostate cancer; metastatic; PSA; general population; PSA; metastatic castration-resistant prostate cancer; metastatic; metastatic castration-resistant prostate cancer; metastatic; previously treated; PSA; metastatic
Mechanism: This phase I trial (NCT04249947) evaluated the safety and efficacy of P-PSMA-101, an autologous TSCM-rich, bone-tropic CAR T-cell therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castrate-resistant prostate carcinoma (mCRPC) Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC

PMID 42641497 PMID 42595485 PMID 41779004 PMID 42320339 PMID 42663310 PMID 41857380 PMID 42346249 PMID 42235186

preliminary evidence

Biomarkers, Tumor

17 linked PMIDs4371 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes
Populations represented: general population; advanced; PSA; localized prostate cancer; localized
Mechanism: LINCRNA-interacting miRNAs and their putative mRNA targets were predicted using NPInter v5.0 and miRDB, respectively, and cross-referenced with differentially expressed secreted proteins Extracellular vesicles (EVs), serving as crucial carriers of biomarkers for tumor diagnosis and prognostic evaluation, as well as drug delivery vehicles and therapeutic targets, making it a research hotspot

PMID 41744286 PMID 42823170 PMID 42391702 PMID 42391902 PMID 42710939 PMID 42544420 PMID 39142499 PMID 42187002

preliminary evidence

FOLH1 protein, human

16 linked PMIDs19592 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: progression-free survival, reported clinical outcomes, recurrence, biochemical recurrence, overall survival, radiographic progression-free survival, objective response rate, response rate
Populations represented: metastatic castration-resistant prostate cancer; metastatic; PSA; general population; PSA; metastatic castration-resistant prostate cancer; metastatic; advanced; PSA; metastatic; PSA
Mechanism: This phase I trial (NCT04249947) evaluated the safety and efficacy of P-PSMA-101, an autologous TSCM-rich, bone-tropic CAR T-cell therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castrate-resistant prostate carcinoma (mCRPC) Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC

PMID 42641497 PMID 42595485 PMID 41779004 PMID 42320339 PMID 42663310 PMID 41857380 PMID 42346249 PMID 42235186

limited evidence

Antineoplastic Agents

15 linked PMIDs111 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, progression-free survival, adverse events, PSA response
Populations represented: general population; metastatic castration-resistant prostate cancer; metastatic; advanced; metastatic castration-resistant prostate cancer; metastatic; PSA
Mechanism: In this study, virtual screening identified four Aurora-A-targeting peptides, among which Peptide-1 showed the most favourable profile These findings suggest that Peptide-1 may act as an Aurora-A-targeting peptide with antiproliferative activity in prostate cancer cells

PMID 42628855 PMID 42578512 PMID 42604690 PMID 42661166 PMID 42632245 PMID 42612458 PMID 42337054 PMID 41665114

preliminary evidence

Lutetium

13 linked PMIDs3199 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, progression-free survival, adverse events, PSA response
Populations represented: metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic castration-resistant prostate cancer; metastatic; PSA; general population; metastatic; PSA; metastatic castration-resistant prostate cancer; metastatic; previously treated; PSA; metastatic
Mechanism: Here, we present PXC-4, a Gastrin Releasing Peptide Receptor (GRPR)-targeting multifunctional PDC based on GRPR antagonist JMV-594 and the cytotoxic payload monomethyl auristatin E (MMAE), for precise PCa therapy Installing of ICG substantially increased cell penetration (6.25-fold at 4 h) and tumor accumulation (3.82-fold at 4 h) of PXC-4, resulting in 89% inhibition of prostate tumor growth via lysosome-mediated toxin release with markedly improved safety

PMID 41979224 PMID 41680989 PMID 42641497 PMID 42595485 PMID 42604690 PMID 42700618 PMID 41896044 PMID 42412178

preliminary evidence

Radiopharmaceuticals

13 linked PMIDs3046 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, progression-free survival, recurrence, biochemical recurrence, adverse events, PSA response
Populations represented: general population; metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic castration-resistant prostate cancer; metastatic; PSA; metastatic; metastatic castration-resistant prostate cancer; advanced; metastatic; PSA
Mechanism: Radiolabeled GRPR antagonists are attractive radionuclide-carriers for TRT, due to their rapid tissue penetration, fast blood/whole-body clearance and inherent biosafety We hereby explore the impact of dosing frequency of a GRPR-radioantagonist with improved tumor retention on therapeutic efficacy

PMID 42728102 PMID 39215130 PMID 42700618 PMID 42235186 PMID 41979224 PMID 41680989 PMID 42641497 PMID 42320339

preclinical evidence only

Receptors, Androgen

11 linked PMIDs527 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes
Populations represented: general population; metastatic; PSA; advanced
Mechanism: The compounds were evaluated against 32 therapeutically relevant targets using molecular docking, MM-GBSA, and molecular dynamics simulations Estrogen receptor α (ERα) and androgen receptor (AR) were identified as the most promising targets, with α-amyrin exhibiting the strongest binding toward AR (MM-GBSA = -100.16 kcal/mol) and β-amyrin toward ERα (-91.94 kcal/mol)

PMID 42632245 PMID 41431399 PMID 38562999 PMID 35163077 PMID 42673562 PMID 42636948 PMID 42794628 PMID 42616976

preliminary evidence

Lutetium-177

9 linked PMIDs3199 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, overall survival, progression-free survival, adverse events, PSA response
Populations represented: metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic castration-resistant prostate cancer; metastatic; PSA; metastatic castration-resistant prostate cancer; metastatic; previously treated; PSA; metastatic
Mechanism: To improve the theranostic efficacy of PSMA-targeted radiopharmaceuticals on patients with medium-to-low PSMA expression, we radiolabeled a series of novel designed PSMA-targeting dimer agents to improve tumor imaging and treatment outcomes under challenging conditions

PMID 41979224 PMID 41680989 PMID 42641497 PMID 42595485 PMID 42565339 PMID 42315637 PMID 42464640 PMID 42471290

preliminary evidence

Nitriles

9 linked PMIDs94 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, quality of life, overall survival
Populations represented: general population; AR-V7; metastatic; metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic; PSA
Mechanism: Mechanistically, RPE promoted resistance independently of its canonical enzymatic activity In this study, we aimed to identify a novel AR-driven signature that can predict prognosis and endows potentially reveal novel therapeutic targets for PRAD

PMID 42399824 PMID 42547555 PMID 38562999 PMID 42710907 PMID 42794467 PMID 42035902 PMID 42794628 PMID 42617299

preliminary evidence

Benzamides

7 linked PMIDs173 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, quality of life, overall survival
Populations represented: general population; metastatic; metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic; PSA
Mechanism: Mechanistically, RPE promoted resistance independently of its canonical enzymatic activity In this study, we aimed to identify a novel AR-driven signature that can predict prognosis and endows potentially reveal novel therapeutic targets for PRAD

PMID 42392697 PMID 42547555 PMID 38562999 PMID 42035902 PMID 42794628 PMID 42617299 PMID 42391446

preliminary evidence

enzalutamide

7 linked PMIDs94 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, quality of life, overall survival
Populations represented: general population; metastatic; metastatic castration-resistant prostate cancer; advanced; metastatic; metastatic; PSA
Mechanism: Mechanistically, RPE promoted resistance independently of its canonical enzymatic activity In this study, we aimed to identify a novel AR-driven signature that can predict prognosis and endows potentially reveal novel therapeutic targets for PRAD

PMID 42795015 PMID 42547555 PMID 38562999 PMID 42035902 PMID 42794628 PMID 42617299 PMID 42391446

moderate-confidence evidence

docetaxel

6 linked PMIDs2538 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: overall survival, reported clinical outcomes, quality of life, adverse events, progression-free survival
Populations represented: metastatic; general population; metastatic castration-resistant prostate cancer; metastatic
Mechanism: Subsequently, via structure-based virtual screening, molecular dynamics simulations, and cellular thermal shift assay (CETSA), emodin-an anthraquinone compound-was identified as a PYCR1-targeting agent

PMID 41833492 PMID 42789110 PMID 42795015 PMID 41665114 PMID 42378957 PMID 42667368

Conflicting Research

higher-confidence evidence

radiotherapy · multiple reported outcomes

58 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

null: 7unknown: 43benefit: 5harm: 3

PMID 39561634 PMID 42570550 PMID 42633701 PMID 41435426 PMID 41437135 PMID 41254344 PMID 42697217 PMID 42648940 PMID 41570179 PMID 42810974

higher-confidence evidence

radical prostatectomy · multiple reported outcomes

53 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 38null: 8benefit: 5harm: 2

PMID 41857380 PMID 42736496 PMID 42421337 PMID 37020054 PMID 42671634 PMID 39943631 PMID 39332749 PMID 32505458 PMID 42648940 PMID 42645643

higher-confidence evidence

Prostate-Specific Antigen · multiple reported outcomes

39 studies

Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 33harm: 1benefit: 2null: 2mixed: 1

PMID 42091407 PMID 42275039 PMID 41872648 PMID 37264206 PMID 42015666 PMID 42161369 PMID 42330502 PMID 41494929 PMID 42303538 PMID 42389925

higher-confidence evidence

androgen deprivation therapy · multiple reported outcomes

17 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 12harm: 1benefit: 2null: 2

PMID 42786231 PMID 41582208 PMID 39547874 PMID 42697217 PMID 36382930 PMID 41565552 PMID 35085341 PMID 42819773 PMID 41807888 PMID 41864432

higher-confidence evidence

radical prostatectomy · multiple reported outcomes

14 studies

Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 10null: 2benefit: 1mixed: 1

PMID 42686439 PMID 41494929 PMID 42113507 PMID 40999072 PMID 41713512 PMID 42426390 PMID 42571475 PMID 42350634 PMID 42794886 PMID 42755244

higher-confidence evidence

Androgen Antagonists · multiple reported outcomes

13 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 8harm: 1benefit: 2null: 2

PMID 42786231 PMID 41582208 PMID 39547874 PMID 42697217 PMID 36382930 PMID 41565552 PMID 35085341 PMID 41807888 PMID 42201380 PMID 42425812

higher-confidence evidence

Androgen Antagonists · multiple reported outcomes

12 studies

Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 10benefit: 1mixed: 1

PMID 41387022 PMID 37945451 PMID 42263846 PMID 41817839 PMID 41833492 PMID 42323390 PMID 42636837 PMID 42380973 PMID 42035902 PMID 42335306

higher-confidence evidence

radiotherapy · multiple reported outcomes

11 studies

Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 10mixed: 1

PMID 42686439 PMID 41494929 PMID 42389925 PMID 42177994 PMID 39922320 PMID 42264093 PMID 42571475 PMID 42794886 PMID 42693211 PMID 42724743

higher-confidence evidence

androgen deprivation therapy · multiple reported outcomes

11 studies

Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 9benefit: 1mixed: 1

PMID 37945451 PMID 42263846 PMID 41817839 PMID 41833492 PMID 42636837 PMID 42380973 PMID 42218356 PMID 42335306 PMID 42789110 PMID 42680612

moderate-confidence evidence

radiotherapy · multiple reported outcomes

8 studies

Status: apparently conflicting; different clinical questions. Population: localized prostate cancer; localized. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

harm: 1unknown: 6null: 1

PMID 41548387 PMID 42430105 PMID 42313395 PMID 42432214 PMID 42810618 PMID 42789071 PMID 41690467 PMID 42818465

higher-confidence evidence

Docetaxel · multiple reported outcomes

5 studies

Status: apparently conflicting; different clinical questions. Population: metastatic castration-resistant prostate cancer; metastatic. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

benefit: 1unknown: 1mixed: 1null: 2

PMID 41033927 PMID 42378957 PMID 42319132 PMID 42667368 PMID 42821836

higher-confidence evidence

radiotherapy · multiple reported outcomes

5 studies

Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

benefit: 1unknown: 3harm: 1

PMID 42457456 PMID 41833492 PMID 42636837 PMID 42218356 PMID 40029246

Failed or Negative Trials

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

randomized controlled trial · 2026 · PMID 42593775

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

randomized controlled trial · 2026 · PMID 42697217

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

randomized controlled trial · 2026 · PMID 42061373

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

randomized controlled trial · 2026 · PMID 42161369

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

randomized controlled trial · 2026 · PMID 41833492

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

randomized controlled trial · 2026 · PMID 41033927

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

randomized controlled trial · 2026 · PMID 42391446

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

randomized controlled trial · 2026 · PMID 42509097

The effect of povidone-iodine-enhanced rectal enema on procedure-related infectious complications before transrectal ultrasound-guided prostate biopsy: A prospective randomized study.

randomized controlled trial · 2026 · PMID 42152336

Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility.

randomized controlled trial · 2026 · PMID 41778764

Emerging and Experimental Research

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.

phase 2 clinical trial · 2027 · PMID 42750816

Rethinking the PSMA-mediated tumor targeting of nanocarrier and potentiating co-delivery of PARP/EZH2 inhibitors for robust prostate cancer treatment.

preclinical or laboratory · 2027 · PMID 42492356

Preclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits.

preclinical or laboratory · 2027 · PMID 42621251

Neddylation-triggered ubiquitination and proteasomal degradation of HELLS inhibits prostate cancer growth via genomic instability.

preclinical or laboratory · 2027 · PMID 42607898

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

randomized controlled trial · 2026 · PMID 41833492

A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).

randomized controlled trial · 2026 · PMID 42532645

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

randomized controlled trial · 2026 · PMID 41862335

Prehabilitation models in patients undergoing radical prostatectomy: A scoping review.

systematic review · 2026 · PMID 42659628

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.

randomized controlled trial · 2026 · PMID 42117295

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

randomized controlled trial · 2026 · PMID 42532646

Evidence Gaps

Detailed risk-of-bias assessment remains limited

PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.

Complete Ranked PubMed Index

The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.

Current Standard Of Care60 records

Rank112.0

Clinical guideline or consensus statement

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

European urology · 2026 · PMID 42457454

BACKGROUND AND OBJECTIVE: To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and treatment of clinically localised prostate cancer (PCa). METHODS: The Panel performed a literature review of all …

Rank112.0

Clinical guideline or consensus statement

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.

BJU international · 2026 · PMID 41979224

Rank112.0

Clinical guideline or consensus statement

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

European urology · 2026 · PMID 42457456

Rank110.0

Clinical guideline or consensus statement

Prostate Cancer Working Group 4 Recap.

European urology focus · 2026 · PMID 42321089

The Prostate Cancer Clinical Trials Working Group (PCWG) recommendations have guided the design and interpretation of prostate cancer trials for more than two decades. Rapid advances in molecular diagnostics, imaging, and systemic therapies have substantially altered the clinical landscape, prompting the recent update to the framework. PCWG4 introduces a shift towards patient-centred terminology and end points, incorporating molecular and imaging biomarkers for trial eligibility and response assessment. The updated…

Rank110.0

Clinical guideline or consensus statement

Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia · 2026 · PMID 42102633

Rank110.0

Clinical guideline or consensus statement

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).

The Journal of urology · 2026 · PMID 41988960

Rank110.0

Clinical guideline or consensus statement

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.

The Journal of urology · 2026 · PMID 42095477

Rank110.0

Clinical guideline or consensus statement

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42561262

[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates a…

Rank110.0

Clinical guideline or consensus statement

[Geriatric assessments and their practical application in uro-oncology : How do we decide on prostate cancer treatment in an age-appropriate way?].

Urologie (Heidelberg, Germany) · 2026 · PMID 42423720

The management of geriatric patients with urological cancers is becoming increasingly important due to rising life expectancy and the growing incidence of such diseases. However, treatment decisions are often based primarily on chronological age or clinical guidelines, whilst insufficient consideration is given to the functional reserve of older patients. Geriatric patients exhibit specific physiological changes such as impaired renal or liver function, sarcopenia, multimorbidity, polypharmacy, malnutrition and cog…

Rank110.0

Clinical guideline or consensus statement

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.

The Journal of urology · 2026 · PMID 42462144

PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part I of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of biochemically recurrent (BCR) and metastatic hormone-sensitive prostate cancer (mHSPC). MATERIALS AND MET…

Rank110.0

Clinical guideline or consensus statement

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.

The Journal of urology · 2026 · PMID 42462145

PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part II of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: The AUA/SUO Advanced Pro…

Rank108.6

Systematic review or meta-analysis

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology · 2026 · PMID 42275039

IMPORTANCE: Magnetic resonance imaging (MRI) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optimal use in population-level screening. OBJECTIVE: To provide consensus recommendations on the acquisition, interpretation, and reporting of prostate MRI for cancer screening. EVIDENCE REVIEW: A systematic review and meta-analysis of randomized clinical trials and prospective cohort studies evaluating MRI for prostate cancer screening was conducted for these international consensus reco…

Rank105.7

Systematic review or meta-analysis

Open, Laparoscopic, Retropubic, or Robotic? A Network Meta-Analysis of Post-Prostatectomy Oncologic Outcomes and Health-Related Quality of Life in Localized Prostate Cancer Patients.

Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42808404

OBJECTIVE: Prostatectomy remains a standard surgical treatment for localized prostate cancer, a malignancy with substantial global incidence and clinical impact in men. Its rapid adoption of surgical modalities has outpaced supporting evidence, resulting in limited consensus in reporting HRQoL and oncologic outcomes. This paper aims to compare the oncologic and Health-Related Quality of Life (HRQoL) outcomes of open (ORP), retropubic (RRP), laparoscopic (LRP), and robot-assisted radical prostatectomy (RARP) in pati…

Rank103.0

Systematic review or meta-analysis

Hugo™ RAS versus da Vinci® for robot-assisted radical prostatectomy in localized prostate cancer: a GRADE-assessed systematic review and meta-analysis of prospective comparative studies.

BMC surgery · 2026 · PMID 42332746

BACKGROUND: The comparative adoption of the Hugo™ robotic-assisted surgery platform for robot-assisted radical prostatectomy (RARP) is increasing; however, the strength and consistency of prospective head-to-head evidence versus da Vinci® remain uncertain. We performed a systematic review and meta-analysis of prospective comparative studies comparing Hugo™ RAS with da Vinci® for localized prostate cancer, incorporating sensitivity analyses and GRADE certainty assessments. METHODS: We searched PubMed, Embase, Scopus…

Rank102.0

Systematic review or meta-analysis

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

European urology · 2026 · PMID 42420069

BACKGROUND: Prostate biopsy is a complex, multi-step procedure lacking standardisation across patient selection, tools, technique, and biopsy strategy, potentially influencing local treatment planning. An international consensus project was initiated to harmonise these aspects. METHODS AND ANALYSIS: A systematic review informed statement development. A modified Delphi process involving 34 international experts was conducted over three rounds. Panellists evaluated 96, 99, and 112 statements in Rounds 1-3, respective…

Rank100.0

Systematic review or meta-analysis

Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration-Sensitive Prostate Cancer.

Clinical genitourinary cancer · 2026 · PMID 41963237

The treatment of metastatic castration-sensitive prostate cancer (mCSPC) is complex, requiring strategies to prevent complications and improve survival outcomes. In resource-limited settings, it is essential to guide clinical practice to ensure patients receive the best available diagnostic and treatment options. This consensus aims to provide updated recommendations for the diagnosis and management of mCSPC in Latin America. This consensus was developed with the participation of clinical experts from multiple Lati…

Rank98.1

Systematic review or meta-analysis

Prehabilitation models in patients undergoing radical prostatectomy: A scoping review.

PloS one · 2026 · PMID 42659628

Prehabilitation, defined as the preoperative optimisation of physical, nutritional, and psychological status, has emerged as a promising strategy to improve postoperative recovery in surgical oncology. However, its application in patients undergoing radical prostatectomy (RP) remains poorly characterised. This scoping review aimed to systematically map existing evidence on prehabilitation models for patients scheduled for RP, with particular focus on delivery formats, intervention components, and outcome measures. …

Rank87.0

Randomized clinical study

Managing testosterone deficiency in primary care: an international expert consensus.

The aging male : the official journal of the International Society for the Study of the Aging Male · 2026 · PMID 42647144

BACKGROUND: Testosterone deficiency (TD) has traditionally been managed by specialists, yet there is growing public demand for general practitioners (GPs) to become involved in the care of these men. Most TD cases initially present to GPs, and common medical conditions associated with TD are already managed by GPs, including obesity, diabetes, anaemia, and impaired mood. However, there has been scant clinical guidance or education for GPs on this topic. AIM: To provide consensus-based expert clinical guidance on th…

Rank78.9

Multicenter clinical study

Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41667886

PURPOSE: We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain. METHODS: This was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study. RESULTS: 85 patients, with a median age of 76 years, were inclu…

Rank74.4

Multicenter clinical study

Pushing the Boundaries of Stereotactic Body Radiation Therapy in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study.

International journal of radiation oncology, biology, physics · 2026 · PMID 41864432

PURPOSE: The CYGNUS study aims to assess both toxicity and efficacy of stereotactic body radiation therapy performed as salvage approach for pelvic nodal metachronous oligorecurrent (PNMOR) hormone-sensitive prostate cancer, in previously irradiated territory. METHODS AND MATERIALS: Inclusion criteria were histologically history of proven prostate cancer, locally treated with a radical intent and a biochemical relapse as defined by the European Association of Urology guidelines. All patients had a radiological susp…

Rank73.0

Multicenter clinical study

Imaging Features That Predict Indeterminate Bone Lesion Outcomes on 18F-DCFPyL PSMA PET/CT Scan: A Multicenter Cohort of 42 Biopsy-Proven Lesions.

Journal of nuclear medicine technology · 2026 · PMID 41916733

Indeterminate bone lesions (IBLs) on prostate-specific membrane antigen (PSMA) PET/CT are common and pose a diagnostic dilemma with important management implications. There is currently no clear consensus on imaging features that predict lesion outcomes. Our study aimed to identify features that characterize IBLs as benign or malignant on 18F-DCFPyL PSMA PET/CT using only biopsy-proven lesions. Methods: In total, 42 IBLs (21 biopsy-proven metastatic prostate cancer and 21 biopsy-proven benign) with pathologic diagn…

Rank50.9

Other PubMed-indexed publication

How i do it: a survey of practice patterns in robot-assisted radical prostatectomy.

Journal of robotic surgery · 2026 · PMID 42934477

Despite the global availability and utilization of robot-assisted radical prostatectomy (RARP), it remains a technically complex operation, with wide variation in training paradigms, surgical technique, and perioperative management. This study examines international RARP practices and aims to identify trends and gaps in clinical practice. A multiple-choice questionnaire consisting of 32 questions was distributed between January and July 2023. A total of 102 responses were received. Responses with ≥ 5 questions with…

Rank50.2

Other PubMed-indexed publication

Prostate MRI quality assessment using PI-QUAL version 2: Comparative analysis between 1.5 T and 3 T scanners and its association with T-staging agreement.

European journal of radiology · 2026 · PMID 41916137

PURPOSE: To assess prostate MRI image quality using Prostate Imaging Quality (PI-QUAL) version 2, to compare quality distributions between 1.5 T and 3 T MRI scanners, and to evaluate the association between image quality and concordance of MRI-based and pathological T-staging. MATERIALS AND METHODS: This retrospective study included 416 patients who underwent preoperative prostate MRI followed by radical prostatectomy between December 2021 and August 2024. MRI examinations were performed using one 1.5 T scanner and…

Rank49.8

Other PubMed-indexed publication

Integrating Multi-Omics and Machine Learning to Reveal a Prognostic Model for Prostate Cancer Metastatic Recurrence Associated with Epithelial-Mesenchymal Transition Features.

Genes · 2026 · PMID 42792911

Background: Prostate cancer (PCa) is a leading cause of cancer-related mortality worldwide, highlighting the need for improved prognostic tools. The integration of artificial intelligence (AI) and machine learning (ML) with multi-omics data offers new opportunities for biomarker discovery and risk stratification. Methods: We integrated bulk transcriptomic data from GSE116918 (training, n = 248) and three cross-cohort consistency evaluation cohorts (TCGA-PRAD, GSE70769, GSE46602), focusing on 1087 epithelial-mesench…

Rank49.2

Other PubMed-indexed publication

[A QUESTIONNAIRE SURVEYON TREATMENT SELECTION FOR PATIENTS WITH ADVANCED PROSTATE CANCER IN JAPAN].

Hinyokika kiyo. Acta urologica Japonica · 2026 · PMID 42374892

We conducted a web-based questionnaire survey targeting urologists in Japan on the real-world treatment selection for patients with advanced prostate cancer. The results were stratified by medical institution category and compared with those reported in the Advanced Prostate Cancer Consensus Conference 2024 (APCCC24). The survey included 124 urologists working at cancer centers/university hospitals (n＝48), public hospitals (n＝32), and general hospitals (n＝44). The proportion of respondents who selected triplet ther…

Diagnosis And Screening239 records

Rank110.0

Systematic review or meta-analysis

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41872314

Rank109.1

Systematic review or meta-analysis

Diagnostic performance of artificial intelligence based on PET/CT for lymph node involvement in prostate cancer: A systematic review and meta-analysis.

International journal of medical informatics · 2026 · PMID 42456599

PURPOSE: This meta-analysis aims to evaluate the diagnostic performance of PET/CT-based artificial intelligence (AI) models for detecting lymph node involvement (LNI) in prostate cancer and compare it with physician readers. METHODS: We systematically searched PubMed, Embase, and Web of Science through March 4, 2025, for studies evaluating PET/CT-based AI (machine learning or deep learning) for LNI detection. Eligible studies used pathology or expert physician reads as reference standards. AI model studies were ass…

Rank108.6

Systematic review or meta-analysis

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology · 2026 · PMID 42275039

Rank106.8

Systematic review or meta-analysisResult signal: null

Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.

Prostate cancer and prostatic diseases · 2026 · PMID 41634333

BACKGROUND: Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men. While multiparametric MRI (mpMRI) is an established tool for detecting clinically significant PCa (csPCa), it is limited by cost, access, and acquisition time. Micro-ultrasound (Micro-US) offers real-time imaging with potential advantages in accessibility and integration into routine care. This systematic review and meta-analysis (SR/MA) aimed to compare the diagnostic accuracy of Micro-US versus mpMRI in detecting csPCa, …

Rank106.6

Systematic review or meta-analysis

Diagnostic accuracy of MRI and PSMA PET/CT for detection of histologically confirmed lymph node metastasis in prostate cancer: A systematic review.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2026 · PMID 42663310

OBJECTIVE: To compare the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and multiparametric magnetic resonance imaging (mpMRI) for the detection of histologically confirmed pelvic lymph node metastases in patients with intermediate- and high-risk prostate cancer. METHODS: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, and Cochrane Library databases were searched from January 2011 to March…

Rank106.4

Systematic review or meta-analysis

Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41857380

OBJECTIVE: The aim of this study was to meta-analyze published data on the diagnostic performance of PSMA PET/CT in detecting lymph node invasion (LNI) in intermediate-risk prostate cancer (PCa) patients, and to discuss whether pelvic lymph node dissection (PLND) can be spared in patients with negative PSMA PET scan. PATIENTS AND METHODS: The PubMed and Embase databases were searched through November 2025 to identify relevant articles. Methodological quality of each study was assessed. Patient-based sensitivity and…

Rank106.4

Systematic review or meta-analysis

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

The lancet. Healthy longevity · 2026 · PMID 42320510

BACKGROUND: Whether differences in sex hormones influence cancer risk in men remains uncertain. We aimed to clarify the association of circulating testosterone, sex hormone-binding globulin (SHBG), and related hormones with risks of cancer death, incident cancer, and incident prostate cancer by means of individual participant data (IPD) meta-analyses. METHODS: A systematic review of the literature using MEDLINE, Embase, OpenGrey, and Mednar was conducted from date of database inception till July 22, 2019, with brid…

Rank106.4

Systematic review or meta-analysis

The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.

Human vaccines & immunotherapeutics · 2026 · PMID 41672480

Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy.…

Rank105.0

Systematic review or meta-analysisCorrection flagged

Genetically adjusted PSA levels for prostate cancer screening.

Nature medicine · 2023 · PMID 37264206

Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utility. In this study, we discovered 128 genome-wide significant associations (P < 5 × 10-8) in a multi-ancestry meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) that explains 9.61% of constitutive PSA…

Rank103.0

Systematic review or meta-analysis

Effects of Green Tea Supplementation on Chemoprevention at Different Stages of Carcinogenesis: A Systematic Review.

Phytotherapy research : PTR · 2026 · PMID 42815945

Green tea catechins have chemopreventive potential; however, the clinical evidence remains inconsistent. This review evaluated the effects of supplementation with green tea derivatives on chemoprevention at different stages of carcinogenesis. PubMed, Embase, Web of Science, Scopus, the Cochrane Library, CINAHL, and Google Scholar were searched for randomised and non-randomised clinical trials in adults. Random-effects meta-analyses were used to estimate relative risks (RRs) and 95% confidence intervals (95% CIs). R…

Rank102.0

Systematic review or meta-analysis

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

European urology · 2026 · PMID 42420069

Rank102.0

Systematic review or meta-analysis

The PSA test for prostate cancer screening: an abridged Cochrane review.

BJU international · 2026 · PMID 42820647

OBJECTIVES: To assess the effects of prostate cancer screening compared to no screening in men with no prior diagnosis of prostate cancer. METHODS: This systematic review represents an update of a prior Cochrane review from 2013, searching multiple databases up to November 2025. We included randomised controlled trials (RCTs) of prostate cancer screening vs no screening. We used standard Cochrane methods, including rating the certainty of the evidence following a Grading of Recommendations, Assessment, Development,…

Rank100.9

Randomized controlled trial

Predictors of fluoroquinolone-resistant bacterial colonization prior to prostate biopsy: a secondary analysis of two randomized trials.

Prostate cancer and prostatic diseases · 2026 · PMID 42036485

BACKGROUND: The prevalence of fluoroquinolone resistant (FQR) rectal bacterial colonization ranges from 15-20%, and FQR colonization increases the risk of prostate biopsy infectious complications. FQR bacteria have been identified in 50% of prostate biopsy infectious complications. However, predictors of FQR remain unclear, so we aimed to elucidate these characteristics. METHODS: A secondary analysis of two multicenter clinical trials (NCT04815876 and NCT04843566) comprising 11 sites was conducted on men who underw…

Rank100.0

Systematic review or meta-analysis

Implementing PI-QUAL in Clinical Practice: A Systematic Review of Reproducibility, Diagnostic Impact, and the Role of Education and Automation.

European journal of radiology · 2026 · PMID 42574769

INTRODUCTION: Variation in prostate MRI image quality persists despite established acquisition guidelines, highlighting the need for objective and reproducible methods of quality assessment. The Prostate Imaging Quality (PI-QUAL) score has been proposed to address this. This systematic review evaluates the inter-reader reproducibility of PI-QUAL scoring, its impact on prostate MRI interpretation, and factors influencing its implementation. METHODS: A systematic review was conducted in accordance with PRISMA guideli…

Rank100.0

Systematic review or meta-analysis

Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis.

Clinical genitourinary cancer · 2026 · PMID 42716838

Circulating tumor DNA (ctDNA) has emerged as a novel detection technique that provides molecular profiles without invasive procedures. This study assessed the prognostic value of ctDNA-based androgen receptor (AR) gene alterations in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide and abiraterone. A comprehensive search was conducted in PubMed, Embase, and the Cochrane Library from January 2016 to April 2025. Studies investigating the prognostic value of AR alterations in ctDNA in …

Rank100.0

Systematic review or meta-analysis

Lipoprotein(a) and Prostate Cancer: A Systematic Review of Observational, Genetic and Mendelian Randomization Evidence.

International journal of molecular sciences · 2026 · PMID 42794701

Cancer is a major cause of morbidity worldwide. Prostate cancer (PCa) is one of the most commonly diagnosed malignancies in men and is clinically heterogeneous, highlighting the need for additional biomarkers that may improve risk stratification. Lipoprotein(a) [Lp(a)] is a genetically determined and increasingly available biomarker, but its relationship with PCa remains uncertain. This systematic review aimed to synthesize observational, genetic, and Mendelian randomization evidence on the associations of circulat…

Rank100.0

Systematic review or meta-analysis

Patient outcome prognosis for external beam radiation therapy using CBCT-based radiomics: a systematic review.

Biomedical physics & engineering express · 2026 · PMID 41435426

Objective. This review investigates the use of cone-beam computed tomography (CBCT) in conjunction with radiomics for external beam radiation therapy (EBRT) in cancer treatment. CBCT, which provides high-resolution, volumetric images, offers a promising tool for precision treatment delivery. By integrating radiomics and quantitative features extracted from CBCT, this review explores potential advancements in tumor characterization, treatment planning, and monitoring treatment responses in personalized cancer therap…

Rank100.0

Systematic review or meta-analysis

Fecal incontinence after prostate cancer irradiation: a systematic literature review.

Prostate cancer and prostatic diseases · 2026 · PMID 41629638

GOAL: Fecal incontinence (FI) is an underrecognized but clinically significant late gastrointestinal toxicity following radiotherapy (RT) for prostate cancer. This systematic review aimed to synthesize current knowledge on the definition and pathophysiology of post-radiation anal continence, as well as prevention strategies, technical considerations, and therapeutic approaches. METHOD: A systematic literature search was conducted according to PRISMA guidelines using the keywords: "Fecal incontinence," "Radiation th…

Rank99.9

Systematic review or meta-analysis

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.

Journal of personalized medicine · 2021 · PMID 35055323

UNLABELLED: Recently, checkpoint inhibitors have been investigated in metastatic prostate cancer, however their overall effect is unclear and needs to be further investigated. OBJECTIVES: The aim of this systematic review is to investigate the oncological response of metastatic castration-resistant prostate cancer patients to immune checkpoint inhibitors. METHODS: Based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement, a systematic review of the literature was conducted t…

Rank99.2

Randomized controlled trial

A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532645

OPTIMAL-PSMA aims to determine the safety and efficacy of a dose-intensified (intense induction followed by a maintenance period) regimen of [177Lu]Lu-PSMA-597 compared with the standard-of-care regimen (every 6 wk for up to 6 doses) in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: OPTIMAL-PSMA is a phase 2, open-label, 2-arm, multicenter, randomized controlled trial of [177Lu]Lu-PSMA-597, a novel prostate-specific membrane antigen (PSMA) peptide with low nontarget organ dosimetry.…

Rank97.2

Phase III clinical trial

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology · 2026 · PMID 42418739

PURPOSE: Metastatic hormone-sensitive prostate cancer (mHSPC) is a heterogeneous disease state with multiple treatment options. Biomarkers are needed for risk stratification and to guide treatment intensification or deintensification. We used a computational histology artificial intelligence-based platform (CHAI) to develop and validate a digital image-only prognostic biomarker in mHSPC with participant-level data from two prospective, phase III randomized controlled trials. METHODS: The CHAI platform extracted qua…

Rank97.0

Randomized controlled trialResult signal: null

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532646

This is a dosimetry analysis of the prospective randomized phase 2 trial RESIST-PC which evaluated the efficacy and safety of 2 injected activity regimens of [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer. Methods: This biinstitutional study randomized patients with metastatic castration-resistant prostate cancer to receive either 6.0 or 7.4 GBq of [177Lu]Lu-PSMA-617 per cycle for up to 4 cycles (1:1 randomization). The γ-images were obtained at the first cycle using…

Rank96.0

Systematic review or meta-analysis

Beyond Nerve Hyperexcitability: Potential Implications of Cerebrospinal Fluid CASPR2 Antibodies for Central Pain Processing in Isaacs Syndrome: A Case-Based Systematic Review.

Pain and therapy · 2026 · PMID 42809178

INTRODUCTION: Isaacs syndrome (IS), or acquired neuromyotonia, is a rare immune-mediated neuromuscular disorder characterized by increased peripheral nerve excitability. Clinically, it manifests with fasciculations, cramps, excessive sweating, and the presence of CASPR2 autoantibodies in the serum. IS can occur as a paraneoplastic condition or may remain idiopathic. METHODS: We report an adult case of IS that prompted a case-based literature review investigating the association between cerebrospinal fluid (CSF) CAS…

Rank92.0

Randomized controlled trialResult signal: harm

Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42531378

PURPOSE: PrOstate cancer Radiation Therapy Outcomes Score (PORTOS) is a 24-gene radiation response signature developed and validated in multiple randomized trials in prostate cancer. Given its basis in general radiation and DNA damage response pathways, we sought to evaluate whether PORTOS could also predict radiotherapy (RT) benefit in breast cancer. EXPERIMENTAL DESIGN: PORTOS scores were calculated from gene expression profiles of 765 tumor samples from SweBCG91RT, a randomized trial of adjuvant whole-breast RT …

Rank92.0

Randomized controlled trial

Intermittent fasting versus continuous calorie energy reduction in prostate cancer patients on active surveillance.

Translational behavioral medicine · 2026 · PMID 42816069

BACKGROUND: Prostate cancer (PCa) is the most common cancer in US men. Nearly half of those diagnosed with PCa present with low-risk disease based on clinical guidelines, for which active surveillance (AS) is increasingly recommended by clinicians to avoid invasive treatment. Obesity is a well-recognized risk factor for poor PCa prognosis. Yet weight loss interventions for PCa patients on AS are limited. PURPOSE: Using the NIH Stage Model for Behavioral Intervention Development as a guide, our Stage 1 study transla…

Evidence Syntheses60 records

Rank112.9

Systematic review or meta-analysis

MRI-derived radiomics for prostate cancer active surveillance: a systematic review.

European journal of radiology · 2026 · PMID 42858633

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.

The Journal of urology · 2026 · PMID 42462144

Rank109.9

Systematic review or meta-analysis

Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42828578

BACKGROUND: Prostate cancer (PCa) and its treatments, notably androgen-deprivation therapy (ADT), are linked to accelerated bone loss, thereby elevating the risk of osteoporosis and fractures. Nevertheless, comprehensive data on the prevalence of osteoporosis and low bone mass (osteopenia) in men with PCa are still limited. OBJECTIVE: To systematically review and meta-analyze the prevalence of osteoporosis and low bone mass in adult men with PCa at all disease stages, and to investigate study-level factors such as …

Rank109.7

Systematic review or meta-analysis

Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients.

Cancer chemotherapy and pharmacology · 2026 · PMID 42786231

PURPOSE: Androgen deprivation therapy (ADT) has been associated with increased cardiovascular and renal risks in prostate cancer patients. We performed a systematic review and meta-analysis of the currently available evidence to evaluate the rates of acute kidney injury (AKI) in prostate cancer patients under ADT. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to October 2024. Eligible observational studies comparing prostate cancer patient…

Rank109.3

Systematic review or meta-analysis

Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.

Prostate cancer and prostatic diseases · 2026 · PMID 41792475

PURPOSE: We systematically reviewed the long-term outcomes of untreated prostate cancer across different risk categories to inform treatment decisions and active surveillance protocols. This comprehensive analysis synthesizes long-term progression data across tumor staging and grading systems. MATERIALS AND METHODS: We conducted a systematic literature search of PubMed, EMBASE, and Cochrane databases (1990-2025) for studies reporting ≥10-year outcomes in untreated or conservatively managed prostate cancer patients.…

Rank109.2

Systematic review or meta-analysisResult signal: null

Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis.

International urology and nephrology · 2026 · PMID 42230439

INTRODUCTION: Robot-assisted radical prostatectomy (RARP) has increasingly replaced open radical prostatectomy (ORP) based on evidence suggesting improved perioperative outcomes and faster recovery. However, few randomized trials directly compare both techniques. This review compares perioperative, functional, and oncological outcomes of RARP versus ORP, integrating newly available high-impact studies. METHODS: A thorough search of major databases was conducted from the inception of each database up to November 202…

Rank109.1

Systematic review or meta-analysis

Diagnostic performance of artificial intelligence based on PET/CT for lymph node involvement in prostate cancer: A systematic review and meta-analysis.

International journal of medical informatics · 2026 · PMID 42456599

Rank108.9

Systematic review or meta-analysis

Digital supportive care in prostate cancer: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42891837

PURPOSE: To map and synthesise the existing evidence on people's perspectives and requirements for patient-facing digital health technologies for use in prostate cancer care delivery. Understanding the preferences of people with prostate cancer and understanding the barriers and facilitators to maximising engagement with digital supportive care healthcare landscape. METHODS: Four electronic databases were searched to identify suitable studies. All identified citations were imported into Covidence systematic review …

Rank108.8

Systematic review or meta-analysis

Intratumoral Human Papillomavirus in Advanced Prostate Cancer: Systematic Review, Meta-Analysis, and Real-World Evidence from the Largest Cohort to Date.

International journal of molecular sciences · 2026 · PMID 42737728

The etiopathogenesis of prostate cancer (PCa) is complex and involves multiple hormonal and environmental factors. Among these, the role of infectious agents remains controversial. Human papillomavirus (HPV) is known to promote carcinogenesis in epithelial tumors and has also been detected, albeit inconsistently, in PCa tissues. This systematic review, meta-analysis, and real-world cohort study aimed to clarify the prevalence and the prognostic role of intratumoral (IT)-HPV detection in locally advanced and metasta…

Rank108.4

Systematic review or meta-analysisResult signal: harm

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41582208

BACKGROUND: Addition of an androgen receptor pathway inhibitor (ARPI) to androgen deprivation therapy (ADT) (ADT + ARPI, i.e., maximal androgen blockade, MAB) improves survival outcomes compared to ADT monotherapy in patients with prostate cancer (PC). It is known that ADT increases the risk of fractures in patients with PC, but it is unclear if this risk is higher with MAB. The aim of this study is to conduct a systematic review and meta-analysis to determine if MAB increases the incidence of fractures compared to…

Rank107.5

Systematic review or meta-analysisResult signal: benefit

Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.

International journal of cancer · 2026 · PMID 42017392

Although immunotherapy has transformed the treatment of several genitourinary malignancies, its role in prostate cancer remains limited. Combining immunotherapy with targeted therapies has emerged as a promising approach to enhance immune responses in prostate cancer. We aimed to systematically evaluate the efficacy and safety of immunotherapy combined with targeted therapy in the treatment of prostate cancer. We conducted a detailed literature search across Embase, Scopus, PubMed, Web of Science, and the Cochrane …

Rank107.4

Systematic review or meta-analysisResult signal: null

Whole-pelvic Versus Prostate-only Radiotherapy in Clinically Node-negative High-Risk Localised Prostate Cancer: A Systematic Review and Meta-analysis with Reconstructed Individual-patient Data.

Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026 · PMID 42727425

SEARCH STRATEGY AND SOURCES OF INFORMATION: MEDLINE, Embase and ClinicalTrials.gov were searched from database inception to May 2026 without language restriction, supplemented by hand-searching the proceedings of major oncology and radiation-oncology congress (2020-2026). AIMS: Whether elective whole-pelvic radiotherapy (WPRT) improves outcomes over prostate-only radiotherapy (PORT) in high-risk localised prostate cancer remains an open question. We synthesised all phase 3 randomised trials and added a reconstructe…

Rank107.0

Systematic review or meta-analysis

Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis.

Clinical genitourinary cancer · 2026 · PMID 42641497

INTRODUCTION: [177Lu]Lu-prostate-specific membrane antigen (PSMA) radioligand therapy can improve outcomes in patients with metastatic castration-resistant prostate cancer, though response is highly variable in clinical practice. We performed a systematic review and meta-analysis to evaluate the prognostic value of pre-therapeutic PSMA PET-derived imaging biomarkers to better inform patient selection for treatment. METHODS: PubMed, EMBASE, Web of Science, and Scopus were searched from inception to December 2025 in …

Rank106.8

Systematic review or meta-analysis

Time to subsequent therapy (TTST) as an endpoint in clinical studies: development of standardized documentation of subsequent therapy through systematic literature review, expert interviews, and Delphi survey.

Journal of cancer research and clinical oncology · 2026 · PMID 42742636

BACKGROUND: The endpoint Time to Subsequent Therapy (TTST) is an intermediate endpoint used in research and regulatory assessments. TTST denotes initiation of subsequent therapy and is a clearly definable, clinically relevant event for healthcare professionals. However, it has not been systematically established to which extent TTST is subjectively meaningful to patients. The objective of this study was to define TTST as a patient-relevant intermediate endpoint. METHODS: The study examined five oncological indicati…

Rank106.8

Systematic review or meta-analysis

Structured and supervised pelvic floor muscle training following confirmed contraction in post-prostatectomy urinary incontinence: a systematic review of randomized controlled trials.

Journal of cancer survivorship : research and practice · 2026 · PMID 40877548

PURPOSE: Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. Post-prostatectomy urinary incontinence (PP-UI) is a common and distressing complication that significantly reduces quality of life in prostate cancer survivors. This systematic review aimed to evaluate the effectiveness of structured and supervised pelvic floor muscle training (PFMT), initiated after confirmed pelvic floor muscle activation, delivered pre- or postoperatively, with or without biofeedback (BF), on symptom sev…

Rank106.8

Systematic review or meta-analysisResult signal: null

Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.

Prostate cancer and prostatic diseases · 2026 · PMID 41634333

Rank106.7

Systematic review or meta-analysis

PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis.

Clinical genitourinary cancer · 2026 · PMID 42586923

PARP inhibitors (PARPi) combined with androgen-receptor signaling inhibitors (ARSI) improve radiographic progression-free survival (rPFS) in homologous-recombination-repair (HRR)-altered metastatic prostate cancer, but effects across disease states and genomic subgroups remain uncertain. We searched MEDLINE, Embase, CENTRAL, Web of Science, and ClinicalTrials.gov through June 2026 for randomized trials of PARPi plus ARSI versus the same ARSI alone in HRR-altered metastatic prostate cancer. Trial-level log hazard ra…

Rank106.6

Systematic review or meta-analysis

Diagnostic accuracy of MRI and PSMA PET/CT for detection of histologically confirmed lymph node metastasis in prostate cancer: A systematic review.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2026 · PMID 42663310

Rank106.4

Systematic review or meta-analysis

The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.

Human vaccines & immunotherapeutics · 2026 · PMID 41672480

Rank106.4

Systematic review or meta-analysis

Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41857380

Landmark Evidence88 records

Rank110.3

Systematic review or meta-analysis

European urology · 2026 · PMID 42091407

Rank110.0

Systematic review or meta-analysis

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41872314

Rank109.4

Systematic review or meta-analysis

Utility of Novel Radiohybrid PSMA Ligands in PET Imaging of Biochemical Recurrence of Prostate Cancer-A Systematic Review and Meta-analysis.

Clinical nuclear medicine · 2025 · PMID 39848242

PURPOSE: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a novel class of radiopharmaceuticals developed for potential theranostic application in prostate cancer (PCa). We aimed to consolidate existing evidence on utility of 18 F-rhPSMA-7/7.3 for PET imaging in PCa in the setting of biochemical recurrence (BCR). PATIENTS AND METHODS: A comprehensive literature search was performed using relevant keywords in PubMed, Scopus, and EMBASE. Articles evaluating utility of 18 F-rhPSMA-7/7.3 PET in PCa B…

Rank109.3

Systematic review or meta-analysis

Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.

European urology oncology · 2025 · PMID 40251100

BACKGROUND AND OBJECTIVE: Focal therapies (FTs) for localized prostate cancer (PCa) are recommended only within prospective registries or clinical trials. In this systematic review and meta-analysis, we aimed to synthesize data from prospective trials evaluating the efficacy and safety of FTs in patients with clinically localized PCa. METHODS: Systematic searches of the PubMed, Scopus, and Web of Science databases identified prospective studies reporting oncological outcomes of FTs in treatment-naïve, clinically lo…

Rank109.3

Systematic review or meta-analysis

Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.

Prostate cancer and prostatic diseases · 2026 · PMID 41792475

Rank108.6

Systematic review or meta-analysis

Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis.

Clinical genitourinary cancer · 2025 · PMID 39571519

BACKGROUND: Androgen-receptor signaling inhibitors (ARSIs) significantly improve survival in systemic therapy for advanced/metastatic prostate cancer (PCa) patients; however possible central nervous system (CNS) toxicity is an unaddressed concern. We aimed to assess and compare the incidence of CNS-related adverse events (AEs) secondary to the treatment of PCa patients with different ARSIs. MATERIALS: In August 2023, a comprehensive seach was conducted in three databases for randomized controlled trials (RCTs) of P…

Rank108.6

Systematic review or meta-analysis

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology · 2026 · PMID 42275039

Rank108.4

Systematic review or meta-analysisResult signal: harm

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41582208

Rank108.0

Systematic review or meta-analysis

A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.

BMC cancer · 2025 · PMID 41299322

BACKGROUND: Prostate cancer (PCa) remains a leading cause of morbidity and mortality among men worldwide, with significant regional variations in prevalence and risk factors. In Nigeria, data on prostate cancer prevalence remain inconsistent due to limited screening and reporting systems. AIM: This systematic review and meta-analysis aimed to synthesise available evidence on the prevalence and associated risk factors of prostate cancer among Nigerian men. METHODS: A systematic search of PubMed, Scopus, Embase, Medl…

Rank107.6

Systematic review or meta-analysis

Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis.

European urology focus · 2026 · PMID 41387022

BACKGROUND AND OBJECTIVE: In metastatic hormone-sensitive prostate cancer (mHSPC), health-related quality of life (HRQoL) is key for personalised treatment decisions. We compared the impact of different mHSPC treatment strategies on HRQoL, tackling a previously unaddressed challenge in comparing the outcomes across different patient-reported outcome measures (PROMs). METHODS: A systematic review was conducted of prospective studies reporting HRQoL outcomes of androgen deprivation therapy (ADT) alone or with placebo…

Rank107.4

Systematic review or meta-analysis

Prognostic value of baseline circulating tumor DNA levels in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

Frontiers in immunology · 2026 · PMID 41859077

BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) remains a clinically aggressive and lethal disease. Circulating tumor DNA (ctDNA), as a minimally invasive biomarker, has shown prognostic utility in several solid tumors. However, its clinical relevance in mCRPC has not been comprehensively elucidated. METHODS: A systematic search of PubMed and EMBASE was conducted from inception to July 2025 to identify studies evaluating the prognostic impact of baseline ctDNA levels in patients with mCRPC. Elig…

Rank107.0

Systematic review or meta-analysis

Effectiveness of Psychological Interventions in Improving Relationship Functioning Among Couples Coping With Prostate Cancer: A Systematic Review and Meta-Analysis.

Psycho-oncology · 2025 · PMID 39804293

OBJECTIVE: There is an increasing amount of literature acknowledging the significance of addressing the psychosocial impact of prostate cancer (PCa) on couples' relationship functioning and well-being. However, research on developing and evaluating psychological interventions for individuals and couples coping with PCa remains limited. This systematic review aimed to critically evaluate and synthesise the effectiveness of psychological interventions in improving the relationship functioning of couples affected by P…

Rank106.8

Systematic review or meta-analysisResult signal: null

Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.

Prostate cancer and prostatic diseases · 2026 · PMID 41634333

Rank106.6

Systematic review or meta-analysis

Diagnostic accuracy of MRI and PSMA PET/CT for detection of histologically confirmed lymph node metastasis in prostate cancer: A systematic review.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2026 · PMID 42663310

Rank106.5

Systematic review or meta-analysis

Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.

Clinical nuclear medicine · 2026 · PMID 41945370

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) tracers have reshaped prostate cancer (PC) imaging, supplementing non-PSMA options such as choline-based agents. However, direct comparative performance data across tracers remain scarce, leaving the optimal choice uncertain. We therefore conducted a systematic review and network meta-analysis (NMA) to assess detection rates (DRs) among PET tracers used for primary and biochemically recurrent PC. METHODS: Following PRISMA…

Rank106.4

Systematic review or meta-analysis

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.

Targeted oncology · 2026 · PMID 42568016

BACKGROUND: Prostate cancer represents the third leading cause of cancer-related mortality in the male population. Androgen deprivation therapy efficacy has been significantly enhanced by the addition of docetaxel chemotherapy and androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, apalutamide, and darolutamide. These agents have demonstrated improvements in both overall survival (OS) and progression-free survival (PFS). Nevertheless, a subset of patients eventually progresses to metasta…

Rank106.4

Systematic review or meta-analysis

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

The lancet. Healthy longevity · 2026 · PMID 42320510

Rank106.4

Systematic review or meta-analysis

Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41857380

Rank106.1

Systematic review or meta-analysis

The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.

European urology · 2024 · PMID 37945451

CONTEXT: Despite the lack of level 1 evidence, metastasis-directed therapy (MDT) is used widely in the management of metastatic prostate cancer (mPCa) patients. Data are continuously emerging from well-designed prospective studies. OBJECTIVE: To summarise and report the evidence on oncological and safety outcomes of MDT in the management of mPCa patients. EVIDENCE ACQUISITION: We searched the PubMed, Scopus, and Web of Science databases for prospective studies assessing progression-free survival (PFS), local contro…

Rank105.7

Systematic review or meta-analysis

Open, Laparoscopic, Retropubic, or Robotic? A Network Meta-Analysis of Post-Prostatectomy Oncologic Outcomes and Health-Related Quality of Life in Localized Prostate Cancer Patients.

Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42808404

Rank105.4

Systematic review or meta-analysis

Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis.

Academic radiology · 2025 · PMID 39755494

RATIONALE AND OBJECTIVES: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0). This system showed promising results in single-center studies. We aim to evaluate the prognostic performance of REC…

Rank105.2

Systematic review or meta-analysis

Focal laser ablation in prostate cancer: a systematic review and meta-analysis.

BJU international · 2026 · PMID 41188055

OBJECTIVE: To evaluate the oncological control and functional outcomes of focal laser ablation (FLA) in the management of localised prostate cancer. METHODS: A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. An electronic search identified studies reporting outcomes of FLA for localised prostate cancer. The primary outcome was oncological control, assessed by recurrence on follow-up biopsy and prostate-specific antigen …

Most Effective Evidence Supported Treatments159 records

Rank112.0

Clinical guideline or consensus statement

Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer.

The American journal of surgical pathology · 2025 · PMID 40444986

A significant subset of well-differentiated prostatic acinar neoplasms with invasive histologic features will not spread outside of the prostate, become symptomatic, or shorten a patient's life even if the tumor is left untreated. Overdiagnosis and overtreatment of these indolent prostate cancers (PCa) remain a significant health care problem despite the improved risk assessment and uptake in acceptance of conservative management. While detection of indolent PCa on an entirely resected prostate is possible, recogni…

Rank112.0

Clinical guideline or consensus statement

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

The Journal of urology · 2026 · PMID 42462144

Rank110.0

Clinical guideline or consensus statement

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.

The Journal of urology · 2026 · PMID 42462145

PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part II of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: The AUA/SUO Advanced Pro…

Rank109.9

Systematic review or meta-analysis

Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42828578

Rank109.7

Systematic review or meta-analysis

Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients.

Cancer chemotherapy and pharmacology · 2026 · PMID 42786231

Rank109.4

Systematic review or meta-analysisResult signal: mixed

Hypertension and risk of cancer recurrence in adult survivors: A systematic review and meta-analysis.

Hypertension research : official journal of the Japanese Society of Hypertension · 2026 · PMID 41203853

As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies…

Rank109.3

Systematic review or meta-analysis

Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.

Prostate cancer and prostatic diseases · 2026 · PMID 41792475

Rank109.0

Systematic review or meta-analysisResult signal: mixed

Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

Does transurethral resection of the prostate before robot-assisted radical prostatectomy have adverse effects on patients diagnosed with prostate cancer: a comparative evidence-based analysis?

Journal of robotic surgery · 2025 · PMID 39976864

In clinical practice, it is not uncommon for a history of trans-urethral resection of the prostate (TURP) to complicate a future robotic-assisted radical prostatectomy (RARP). This study aims to determine if prior TURP adversely affects outcomes in subsequent RARP, analyzing perioperative, functional, and oncological results between the procedures. Research published in English before September 2024 was systematically reviewed using Web of Science, PubMed, Cochrane Library, and the EMBASE. Review Manager 5.4 was us…

Rank107.5

Systematic review or meta-analysisResult signal: benefit

Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.

International journal of cancer · 2026 · PMID 42017392

Rank107.2

Systematic review or meta-analysis

Prognosis of radical prostatectomy combined with pelvic lymph node dissection in patients with intermediate- and high-risk prostate cancer: a systematic review and single-arm meta-analysis.

International urology and nephrology · 2026 · PMID 40788468

BACKGROUND: The efficacy of pelvic lymph node dissection (PLND) in enhancing the prognosis of patients with intermediate- and high-risk prostate cancer (PCa) has been a subject of ongoing debate. It is noteworthy that a majority of existing studies on this topic are retrospective and have shorter follow-up durations. This meta-analysis is therefore purposed to assess the prognosis of intermediate to high-risk PCa patients who have undergone a combination of radical prostatectomy (RP) and PLND. METHODS: This study s…

New Research Last 24 Months369 records

Rank110.0

Systematic review or meta-analysis

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41872314

Rank109.3

Systematic review or meta-analysis

Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.

Prostate cancer and prostatic diseases · 2026 · PMID 41792475

Rank108.6

Systematic review or meta-analysis

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology · 2026 · PMID 42275039

Rank108.4

Systematic review or meta-analysisResult signal: harm

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41582208

Rank107.6

Systematic review or meta-analysis

Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis.

European urology focus · 2026 · PMID 41387022

Rank106.8

Systematic review or meta-analysisResult signal: null

Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.

Prostate cancer and prostatic diseases · 2026 · PMID 41634333

Rank106.6

Systematic review or meta-analysis

Diagnostic accuracy of MRI and PSMA PET/CT for detection of histologically confirmed lymph node metastasis in prostate cancer: A systematic review.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2026 · PMID 42663310

Rank106.4

Systematic review or meta-analysis

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

The lancet. Healthy longevity · 2026 · PMID 42320510

Rank106.4

Systematic review or meta-analysis

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.

Targeted oncology · 2026 · PMID 42568016

Rank106.4

Systematic review or meta-analysis

Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41857380

Rank106.0

Systematic review or meta-analysis

Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR).

European urology oncology · 2026 · PMID 42823260

BACKGROUND: Whether freedom from biochemical recurrence (BCR) at 5 yr after definitive radiotherapy (RT) for localized prostate cancer (PCa) represents a durable cure remains uncertain. OBJECTIVE: To evaluate the association between the timing of BCR after RT and the long-term risks of distant metastasis (DM) and PCa-specific mortality (PCSM), overall and according to treatment intensity, including outcomes by BCR timing (≤5 yr, >5 yr, or no BCR). DESIGN, SETTING, AND PARTICIPANTS: Post hoc individual patient data …

Rank105.7

Systematic review or meta-analysis

Open, Laparoscopic, Retropubic, or Robotic? A Network Meta-Analysis of Post-Prostatectomy Oncologic Outcomes and Health-Related Quality of Life in Localized Prostate Cancer Patients.

Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42808404

Rank103.0

Systematic review or meta-analysis

Effects of Green Tea Supplementation on Chemoprevention at Different Stages of Carcinogenesis: A Systematic Review.

Phytotherapy research : PTR · 2026 · PMID 42815945

Rank102.1

Systematic review or meta-analysis

Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).

The Prostate · 2026 · PMID 42633701

BACKGROUND: Stereotactic ablative radiotherapy (SABR) is emerging as an alternative treatment for patients with locally recurrent prostate cancer after previous radiation. This approach allows for precise target coverage while limiting toxicity to surrounding organs. However, reported outcomes following re-irradiation of the prostate with SABR remain variable. This systematic review and meta-analysis therefore evaluated the efficacy and toxicity of prostate re-irradiation with SABR. METHODS: A systematic review and…

Rank102.0

Systematic review or meta-analysis

The PSA test for prostate cancer screening: an abridged Cochrane review.

BJU international · 2026 · PMID 42820647

Rank102.0

Systematic review or meta-analysis

Prostate cancer and prostatic diseases · 2026 · PMID 41629638

Rank100.0

Systematic review or meta-analysis

Telesurgery in prostate cancer: a systematic review of clinical applications and future directions.

Prostate cancer and prostatic diseases · 2026 · PMID 41721057

INTRODUCTION: Telesurgery represents an emerging frontier in the surgical management of prostate cancer, offering innovative solutions to expand access to specialized care across geographic and institutional barriers. This systematic review aims to evaluate the feasibility, clinical outcomes, and technical considerations of telesurgical applications in the treatment of prostate cancer. METHODS: A comprehensive literature search was conducted across MEDLINE (via PubMed), Embase, Scopus, and Web of Science in June 20…

Rank99.7

Randomized controlled trialResult signal: benefit

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

The Lancet. Oncology · 2026 · PMID 42697217

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer causes substantial adverse effects. Despite consistent national and international guideline recommendations, supervised exercise is rarely integrated into care. We aimed to determine whether the STAMINA lifestyle intervention, embedded into cancer care, would improve cancer-specific quality of life and fatigue versus behaviourally Optimised Usual Care in men with prostate cancer in England. METHODS: STAMINA was a multicentre, randomised trial done a…

Rank99.7

Randomized controlled trialResult signal: mixed

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

JAMA · 2026 · PMID 42593775

IMPORTANCE: The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest. OBJECTIVE: To determine whether stereotactic body radiotherapy (SBRT) was superior to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in terms of patient-reported urinary irritative/obstructive and bowel quality of life and disease-free survival (DFS). DESIGN, SETTING, AND PARTICI…

Preclinical Research96 records

Rank100.0

Systematic review or meta-analysis

Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications-A Systematic Review.

Clinical genitourinary cancer · 2026 · PMID 42624022

Prostate cancer disproportionately affects Sub-Saharan African men, who often present with aggressive, late-stage disease. This systematic review synthesizes contemporary evidence on the immunophenotyping and molecular patterns of prostate cancer in East Africa to inform regional screening and precision oncology strategies. Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed, Scopus, and Web of Science for studies published between January 1, 2011 and December 31, 2025. The review prot…

Rank100.0

Systematic review or meta-analysis

Antitumor activity of scorpion venom-derived peptides: A meta-analysis of preclinical studies.

Pharmacological research · 2026 · PMID 42628855

Despite advances in cancer therapeutics, there are still challenges in improving drug toxicity and selectivity. Peptides from various venous species have recently garnered attention for their biopharmaceutical potential, particularly in cancer. The present study aimed to conduct a meta-analysis of the antitumor activity of scorpion venom-derived peptides (SVDPs) previously reported in preclinical models. The bibliographic research included original and review articles written in English published from 2015 to 2026.…

Rank96.0

Systematic review or meta-analysis

PROK1 Expression Is Associated With Prognosis and May Influence Response to Antiandrogen Therapy in Prostate Cancer.

Prostate cancer · 2026 · PMID 42812728

BACKGROUND: Previous studies have found that PROK1 is involved in the progression of tumors. This study aims to investigate the association of PROK1 with prognosis and its potential relationship with the efficacy of antiandrogen therapy in prostate cancer and to explore the underlying mechanisms. METHODS: A total of 498 and 1249 prostate cancer samples were obtained from the TCGA and GEO databases, respectively. First, the expression of PROK1 in prostate cancer was analyzed in the bulk RNA sequencing dataset, and t…

Rank85.0

Randomized clinical study

Salvage treatment strategies for recurrence after radical prostatectomy: Current status, challenges, and future directions.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026 · PMID 42705104

OBJECTIVE: Recurrence after radical prostatectomy (RP) remains a major clinical challenge in prostate cancer and is characterized by substantial heterogeneity in recurrence patterns. This review aimed to summarize current evaluation strategies, recent advances in salvage treatment, and future directions for patients with recurrence after RP. METHODS: We conducted a structured narrative review of PubMed/MEDLINE, Embase, Web of Science Core Collection, and the Cochrane Library from database inception to 20 August 202…

Rank65.0

Prospective cohort study

Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead.

Clinical genitourinary cancer · 2026 · PMID 42669222

Prostate cancer is the second most common malignancy in men worldwide and a leading cause of cancer-related mortality, yet the trajectory of its research has consistently lagged behind cancers of comparable burden. This Perspective argues that the persistent gap is not primarily a consequence of biological difficulty, but the compounded product of structural forces: a late and fragmented patient advocacy movement shaped by stigma and norms of masculinity; sustained disparities in public research funding; decades of…

Rank45.0

Other PubMed-indexed publication

The effects of long-term aerobic exercise on prostate cancer-induced adipose tissue wasting: Browning to the rescue?

Cellular signalling · 2026 · PMID 42349705

The loss of adipose tissue has been emerging as a key component of cancer-related body wasting. One of the underlying causes suggested for this loss is the browning of the white adipose tissue. However, exercise, a promising therapeutic strategy for cancer-related body wasting, might also promote white adipose tissue browning. It remains unclear how similar or distinct the browning process and its effects are when triggered by exercise in cancer compared to cancer alone. This study investigated the retroperitoneal …

Rank45.0

Other PubMed-indexed publication

Histoprotective and antiproliferative effects of Raloxifene treatment during prostate carcinogenesis in rats.

Toxicology and applied pharmacology · 2026 · PMID 42447936

The ability of prostate cancer to progress to castration-resistant disease underscores the importance of study on adjuvant therapies. Recent research suggests estrogen receptors as possible therapeutic targets in neoplasias and they can be modulated by drugs such as Raloxifene. In this context, this study aimed to evaluate the effects of Raloxifene therapy during prostatic carcinogenesis through exposure to the carcinogen N-methyl-N-nitrosourea (MNU). To this end, male Fisher 344 rats underwent a tumor induction pr…

Rank45.0

Other PubMed-indexed publication

p53-loss induced prostatic epithelial cell plasticity and invasion is driven by a crosstalk with the tumor microenvironment.

Cell death & disease · 2025 · PMID 39865080

Prostate cancer is a heterogeneous disease with a slow progression and a highly variable clinical outcome. The tumor suppressor genes PTEN and TP53 are frequently mutated in prostate cancer and are predictive of early metastatic dissemination and unfavorable patient outcomes. The progression of solid tumors to metastasis is often associated with increased cell plasticity, but the complex events underlying TP53-loss-induced disease aggressiveness remain incompletely understood. Using genetically engineered mice, we …

Rank45.0

Other PubMed-indexed publication

Biodistribution of PET radiotracers in tumor-bearing TRAMP mice administered by retroorbital or jugular vein injections.

Scientific reports · 2024 · PMID 39215130

Nuclear medicine is an important tool for use in molecular imaging of important biological processes. Methods for intravenous delivery of radiotracers remains a challenge, with tail vein injections demonstrated to be technically difficult and lacking in reproducibility. Other intravenous methods include jugular vein (JV) injection, which requires a more invasive and precise microsurgical technique. Although the retroorbital (RO) sinus drains directly into the JV, and RO injections are minimally invasive and simpler…

Rank45.0

Other PubMed-indexed publication

Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.

Cancer letters · 2024 · PMID 38945201

The tumor microenvironment (TME) of prostate cancer (PCa) is characterized by high levels of immunosuppressive molecules, including cytokines and chemokines. This creates a hostile immune landscape that impedes effective immune responses. The interleukin-1 (IL-1) receptor antagonist (IL1RN), a key anti-inflammatory molecule, plays a significant role in suppressing IL-1-related immune and inflammatory responses. Our research investigates the oncogenic role of IL1RN in PCa, particularly its interactions with muscarin…

Rank42.0

Other PubMed-indexed publication

Vaccine-Based Immunotherapy for Head and Neck Cancers.

Cancers · 2021 · PMID 34885150

In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients benefiting from the treatment. Promising effects of therapeutic vaccination led the FDA to approve the use of the first therapeutic vaccine in prostate cancer in 2010. Research in the field of therapeutic vaccination, including possible synergistic effects with anti-PD(L)1 treatments, is evolving each year, and many va…

Rank42.0

Other PubMed-indexed publication

Effect of Copper and Selenium Supplementation on the Level of Elements in Rats' Femurs under Neoplastic Conditions.

Nutrients · 2022 · PMID 35334941

A study was conducted to determine the effect of long-term supplementation with selenium and copper, administered at twice the level used in the standard diet of rats, on the content of selected elements in the femoral bones of healthy rats and rats with implanted LNCaP cancer cells. After an adaptation period, the animals were randomly divided into two experimental groups. The rats in the experimental group were implanted with prostate cancer cells. The rats in the control group were kept in the same conditions as…

Rank33.8

Preclinical or laboratory study

Incomplete thermal ablation accelerates local and systemic tumor progression in an immunocompetent prostate cancer model.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 41813588

BACKGROUND: This study aims to evaluate the effects of sublethal hyperthermia on tumor growth of residual tumors in an immune-competent mouse model of prostate cancer. MATERIALS AND METHODS: The study progressed through sequential experiments to assess the effects of incomplete thermal ablation, starting with in vitro tests of sublethal heat on Myc-CaP cell growth, followed by in vivo tumor growth studies on FVB mice (n = 84), proteomic analysis of residual tumors, immunohistochemical evaluation of markers of cellu…

Rank33.5

Preclinical or laboratory studyResult signal: null

Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry.

European journal of nuclear medicine and molecular imaging · 2026 · PMID 42350617

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is an established treatment for advanced prostate cancer, but renal radiation exposure remains a major safety concern, as no clinically established nephroprotective strategy exists. Preclinical data suggest metformin to reduce renal radiopharmaceutical retention by interfering with tubular reabsorption. This study aimed to investigate the effect of metformin on renal and tumor dosimetry in PSMA RPT patients. METHODS: 57 pa…

Rank33.0

Preclinical or laboratory study

Identification and verification of immunogenic cell death-related signatures derived from bone metastasis of prostate cancer based on multi-omics and machine learning algorithms.

Computational biology and chemistry · 2026 · PMID 42419189

BACKGROUND: Prostate cancer (PCa) is a prevalent urological malignancy in men, with bone metastasis occurring in the majority of patients, often leading to poor clinical outcomes. Despite its clinical significance, reliable prognostic biomarkers for metastatic PCa remain limited. Immunogenic cell death (ICD), a regulated form of cell death, has emerged as a key modulator of the tumor immune microenvironment (TIME) and a potential determinant of the immunotherapy response. However, the functional role of ICD in PCa …

Rank32.0

Preclinical or laboratory study

Immunometabolic effects of oral testosterone for castration-resistant prostate cancer in the ACROBAT trial.

Molecular cancer research : MCR · 2026 · PMID 42814510

High-dose testosterone is an emerging treatment option for selected patients with castration-resistant prostate cancer (CRPC), but its efficacy is limited by frequent primary and acquired resistance. Preclinical studies suggest that high-dose testosterone induces tumor metabolic reprogramming that promotes resistance, however clinical validation is lacking. In the prospective ACROBAT trial, we performed longitudinal plasma metabolomic profiling and high-dimensional immune cell phenotyping of 10 patients with CRPC t…

Rank30.0

Preclinical or laboratory study

Selective anticancer activity of imidazolium salts in prostate cancer cells via ROS-mediated mechanisms.

Bioorganic chemistry · 2026 · PMID 42520517

Prostate cancer remains a major therapeutic challenge, particularly in advanced and treatment-resistant disease. Imidazolium salts (IS) are tunable compounds with reported biological activity and potential anticancer applications. In this study, a series of structurally tailored IS, including C10MImCl, C16MImCl, C16BnImCl, and related analogues, was synthesized and evaluated in androgen-independent prostate cancer cells (PC-3 and DU145), androgen-responsive LNCaP cells, and non-tumorigenic prostate epithelial cells…

Rank30.0

Preclinical or laboratory study

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.

Gut microbes · 2026 · PMID 42252578

Endocrine drugs serve as the cornerstone of prostate cancer treatment. Flutamide, a representative first-generation antiandrogen, has been relegated to the treatment of recurrent prostate cancer due to novel drug development and therapeutic resistance. Our study shows the gut microbiota contributes to this resistance. Specifically, gut bacteria metabolize Flutamide into FLU-6 (a nitroreduction product) and FLU-9 (an acetylation product), involving species like Escherichia coli. Gene knockout revealed E. coli nfsA a…

Rank30.0

Preclinical or laboratory study

Diagnostic and prognostic value of lncSPATA8-AS1 in prostate cancer and its regulatory effect on tumor progression.

Cancer biology & therapy · 2026 · PMID 42187002

BACKGROUND: Long noncoding RNAs (lncRNAs) have significant impacts on the occurrence and development of many cancers. However, their effects and mechanisms on prostate cancer (PCa) remain largely unknown. The study was to explore the influence of lncSPATA8-AS1 on PCa and its molecular mechanism of action. METHODS: In the GSE179321 dataset, lncSPATA8-AS1, which was upregulated in PCa tumor tissues, was selected. The expression levels of lncSPATA8-AS1, miR-328-5p, and EPHB2 were detected using RT-qPCR. In vitro exper…

Rank30.0

Preclinical or laboratory study

Interaction between ZMIZ2 and AR promotes prostate cancer proliferation in vitro and in vivo.

Cancer biology & therapy · 2026 · PMID 41431399

BACKGROUND: ZMIZ2, an androgen receptor (AR) transcriptional co-regulator, promotes prostate cancer (PCa) cell proliferation by interacting with AR to upregulate genes associated with cell proliferation; however, its specific cooperative mechanisms remain unclear. This study aims to elucidate these mechanisms. MATERIALS AND METHODS: We analyzed the expression level and prognostic significance of ZMIZ2 in PCa using bioinformatics methods. ZMIZ2 expression and its correlation with the Gleason score were analyzed usin…

Rank30.0

Preclinical or laboratory study

Ethnopharmacological landscape of Azadirachta indica (Neem): Phytochemical diversity bridging traditional heritage and modern medicine.

Journal of ethnopharmacology · 2026 · PMID 42320775

ETHNOPHARMACOLOGICAL RELEVANCE: Azadirachta indica A. Juss. (neem) is a cornerstone of traditional medicine across tropical regions, recognized for its broad-spectrum therapeutic applications. However, the translation of its extensive ethnopharmacological legacy into evidence-based therapy is hindered by fragmented reports and a lack of systematic integration. AIM OF THE REVIEW: This narrative review aims to provide a quantitative and mechanistic synthesis of neem's phytochemical diversity and pharmacological lands…

Rank30.0

Preclinical or laboratory study

ZIF-8 nanoplatform coordinating Zn2+ overload and STING activation for enhanced prostate cancer immunotherapy.

International journal of pharmaceutics: X · 2026 · PMID 42519115

Zinc homeostasis dysregulation is a significant feature in prostate cancer (PCa), characterized by a marked decrease in intracellular Zn2+ concentration. High levels of Zn2+ inhibit PCa cell proliferation, enhance drug sensitivity, and are closely linked to antitumor immune activation. Here, zeolitic imidazolate framework-8 (ZIF-8) was employed to encapsulate pyrithione (PT), a Zn2+ ionophore, and cyclic diguanylate (c-di-GMP), a STING agonist, followed by encapsulation with ovalbumin (OVA). In this nanoplatform (P…

Rank30.0

Preclinical or laboratory study

MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.

Cell cycle (Georgetown, Tex.) · 2026 · PMID 42333722

Understanding molecular pathways in prostate cancer (PCa) is essential. This study demonstrates that miR-6833-3p plays a key role in prostate tumorigenesis via multi-omics integration and functional validation. Expression levels of miR-6833-3p, NUMB, and NOTCH1 were measured in PCa cell lines. The direct regulation of NUMB by miR-6833-3p was confirmed via dual-luciferase reporter assays with mutagenesis. Functional effects were examined using NUMB plasmids or miR-6833-3p mimics. Cell function assays and xenograft m…

Rank30.0

Preclinical or laboratory study

Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer.

Journal of enzyme inhibition and medicinal chemistry · 2026 · PMID 41665114

Docetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism. It is highly expressed in various cancers and promotes malignant progression, yet its role in DTX resistance in prostate cancer remains unclear. In this study, bioinformatics analyses and in vitro/vivo experiments demonstrated that interfering with PYCR1 expression modulates the sensitivity of prostate cancer ce…

Rank30.0

Preclinical or laboratory study

Evolution of PSMA-GRPr heterobivalent radiolabeled conjugates for the diagnosis and therapy of prostate cancer.

European journal of medicinal chemistry · 2026 · PMID 42235186

This review focuses on heterobivalent conjugates with therapeutic and diagnostic action for targeted delivery to prostate cancer (PC) cells. All currently published studies on this topic, identified in the literature by February 2026, were analyzed in this review. The review begins with an introduction to targeted delivery and the development of the heterobivalent conjugate concept. Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing…

Promising Experimental Therapies70 records

Rank99.2

Randomized controlled trial

A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532645

Rank99.2

Randomized controlled trial

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

European urology · 2026 · PMID 41833492

Cancer research communications · 2026 · PMID 42636061

PURPOSE: Inhibitors of the ataxia-telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anticancer activity with platinum compounds in preclinical models. We therefore conducted a phase II study of the ATR inhibitor berzosertib + carboplatin versus docetaxel + carboplatin in metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: Patients previously treated with at least one androgen receptor pathway inhibitor and taxane…

Rank95.5

Randomized controlled trial

Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.

Clinical genitourinary cancer · 2026 · PMID 42303538

BACKGROUND: We previously reported results from a randomized phase 2 trial evaluating a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase (PAP) versus placebo (GM-CSF vaccine adjuvant alone) in patients with PSA-recurrent, nonmetastatic, noncastrate prostate cancer (NCT01341652). The primary endpoint of 2-year metastasis-free survival (MFS) was not different between the treatment arms. This trial was reopened for long-term evaluation. METHODS AND RESULTS: The median follow-up for long-term overall survival …

Rank95.0

Randomized controlled trial

Ablative radiotherapy in castration-resistant prostate cancer.

BJU international · 2026 · PMID 42389925

OBJECTIVE: To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration-resistant prostate cancer (CRPC) a single-centre randomised trial was initiated. PATIENTS AND METHODS: This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate-specific membrane antigen-positive bone or lymph node metastases developing prostate-specific antigen (PSA) progression during androgen deprivation (ADT) or ADT and androgen-receptor targeted ther…

Rank92.0

Randomized controlled trial

Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study).

Bone · 2026 · PMID 42035902

Androgen deprivation therapy has a negative effect on bone mineral density and trabecular bone score in prostate cancer patients. The addition of androgen receptor pathway inhibitors can result in worsened skeletal fragility. BonEnza is a prospective phase II trial in which metastatic hormone sensitive prostate cancer patients were randomized to receive androgen deprivation therapy plus enzalutamide with (EZ arm) or without (E arm) the addition of zoledronic acid. Bone quantity and quality parameters were evaluated…

Rank92.0

Randomized controlled trialResult signal: harm

European journal of nuclear medicine and molecular imaging · 2026 · PMID 42201380

PURPOSE: Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [177Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT. METHODS: In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-…

Rank67.6

Phase I clinical trial

Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41779004

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapies have shown potential in solid tumors. A higher proportion of stem cell-like memory T cells (TSCM) in CAR T-cell products could enhance engraftment, persistence, and prolong immune activity. This phase I trial (NCT04249947) evaluated the safety and efficacy of P-PSMA-101, an autologous TSCM-rich, bone-tropic CAR T-cell therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castrate-resistant prostate carcinoma (mCRPC). Second…

Prospective Cohort Studies103 records

Rank108.6

Systematic review or meta-analysis

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology · 2026 · PMID 42275039

Rank107.5

Systematic review or meta-analysisResult signal: null

KangDuo system versus da Vinci system for robot-assisted radical prostatectomy: a systematic review and meta-analysis based on prospective studies.

Journal of robotic surgery · 2025 · PMID 41075042

Rank106.8

Systematic review or meta-analysisResult signal: null

Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.

Prostate cancer and prostatic diseases · 2026 · PMID 41634333

Rank106.4

Systematic review or meta-analysis

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

The lancet. Healthy longevity · 2026 · PMID 42320510

Rank100.0

Systematic review or meta-analysis

Empirically derived dietary patterns and prostate cancer risk: a systematic review and meta-analysis of prospective cohorts.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 41877536

Rank100.0

Systematic review or meta-analysis

Lipoprotein(a) and Prostate Cancer: A Systematic Review of Observational, Genetic and Mendelian Randomization Evidence.

International journal of molecular sciences · 2026 · PMID 42794701

Rank99.0

Randomized controlled trial

MRI-informed urethral preservation strategy for early continence recovery after robot-assisted radical prostatectomy: a multicenter randomized controlled trial.

Journal of robotic surgery · 2026 · PMID 42645643

To evaluate whether an MRI-informed urethral preservation strategy based on preoperative membranous urethral length (MUL) and prostatic apical morphology improves early continence recovery after robot-assisted radical prostatectomy (RARP). This multicenter, prospective, randomized, assessor-blinded exploratory trial enrolled 100 patients with biopsy-confirmed prostate cancer scheduled for transperitoneal RARP. Patients were randomly assigned in a 1:1 ratio to an MRI-informed urethral preservation group or a convent…

Rank98.1

Randomized controlled trial

Impact of peritoneal bladder flap in robot-assisted radical prostatectomy patients on lymphoceles: a prospective randomised trial.

World journal of urology · 2025 · PMID 40044802

OBJECTIVE: To test the impact of fixing a peritoneal flap of the bladder to the plexus Santorini as final step of robot-assisted radical prostatectomy (RARP) to reduce the incidence of symptomatic lymphoceles and postoperative complications. PATIENTS AND METHODS: A two-armed prospective randomised, controlled, single-centre trial on 1080 patients with prostate cancer who underwent RARP with bilateral pelvic lymph node dissection was carried out. Patients in the intervention arm received fixation of the peritoneal f…

Rank98.1

Systematic review or meta-analysis

Prehabilitation models in patients undergoing radical prostatectomy: A scoping review.

PloS one · 2026 · PMID 42659628

Rank97.0

Randomized controlled trial

PURPOSE: The safety and effectiveness of water vapor for ablation of prostate tissue was assessed in men with intermediate-risk localized prostate cancer (PCa). MATERIALS AND METHODS: A prospective, multicenter, single-arm study (VAPOR 2) was conducted in 235 men at 26 centers across the United States in men ≥ 50 years, with Gleason Grade Group 2 PCa confined to a single Prostate Imaging Reporting and Data System 3 or 4 abnormality on multiparametric MRI fusion biopsy, PSA level ≤ 15 ng/mL, and clinical stage ≤ T2c…

Rank77.4

Multicenter clinical study

Impact of radiotherapy on quality of life reported by elderly patients.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42068504

OBJECTIVES AND PURPOSES: To determine the impact of radical radiotherapy (RT) treatment on the quality of life reported by elderly patients. MATERIALS AND METHODS: A prospective multicenter study was conducted in 8 national centers. Patients over 70 years old who had an indication for radical RT were included. All patients were initially assessed with the Geriatric-8 (G8) scale, ECOG PS, Nutriscore, SARC_F (sarcopenia questionnaire), and completed two patient-reported outcomes measure (PROMs) questionnaires: the EO…

Quality Of Life77 records

Rank107.6

Systematic review or meta-analysis

Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis.

European urology focus · 2026 · PMID 41387022

Rank106.4

Systematic review or meta-analysisResult signal: benefit

The impact of prehabilitation on postoperative outcomes in patients undergoing radical prostatectomy for prostate cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42736496

PURPOSE: Preoperative rehabilitation training can optimize functional reserve before radical prostatectomy (RP), thereby improving postoperative outcomes. However, its effects on urinary incontinence, erectile function, and quality of life (QoL) remain controversial. This study systematically evaluated these outcome measures. METHODS: Data from randomized controlled trials (RCTs) were retrieved from the PubMed, Cochrane Library, Embase, and CINAHL databases. The risk of bias was assessed using the RoB-2 tool, and m…

Rank105.7

Systematic review or meta-analysis

Open, Laparoscopic, Retropubic, or Robotic? A Network Meta-Analysis of Post-Prostatectomy Oncologic Outcomes and Health-Related Quality of Life in Localized Prostate Cancer Patients.

Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42808404

Rank102.0

Systematic review or meta-analysis

The PSA test for prostate cancer screening: an abridged Cochrane review.

BJU international · 2026 · PMID 42820647

Rank100.0

Systematic review or meta-analysis

Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy.

The Prostate · 2026 · PMID 42542970

BACKGROUND: Hot flashes are common and often debilitating side effects of castration therapy; a cornerstone in the treatment of metastatic prostate cancer (PCa) as well as in localized or locally advanced PCa when combined with radiotherapy. The evidence for relieving vasomotor symptoms is limited. This systematic review presents both pharmacological and non-pharmacological interventions for treating hot flashes in men with PCa undergoing castration therapy, primarily androgen deprivation therapy (ADT). METHODS: a …

Rank99.7

Randomized controlled trialResult signal: mixed

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

JAMA · 2026 · PMID 42593775

Rank99.7

Randomized controlled trialResult signal: benefit

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

The Lancet. Oncology · 2026 · PMID 42697217

Rank99.2

Randomized controlled trialResult signal: benefit

The 24-mo Outcomes from the Noninferiority Randomised Controlled Trial of Surgery for Men with Urodynamic Stress Incontinence After Prostate Surgery (MASTER).

European urology focus · 2026 · PMID 42648940

BACKGROUND: The artificial urinary sphincter (AUS) is the most common surgical procedure for persistent stress urinary incontinence (SUI) after prostate surgery, whereas the male sling is a newer alternative. OBJECTIVE: To compare the 24-mo outcomes of the sling versus the AUS. DESIGN, SETTINGS, AND PARTICIPANTS: This was an unblinded, noninferiority randomised controlled trial including men from 27 UK urological centres with bothersome urodynamic SUI after prostate surgery. INTERVENTION: Men were randomised to rec…

Rank98.9

Randomized controlled trialResult signal: null

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Clinical genitourinary cancer · 2026 · PMID 42509097

BACKGROUND: Head-to-head comparisons between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) have shown comparable survival benefits in patients with castration-resistant prostate cancer (CRPC). However, the quality of life (QoL) associated with these agents has not been directly compared. We conducted a sub-analysis to evaluate longitudinal changes in QoL within each treatment arm. METHODS: The ENABLE study for PCa, an investigator-initiated, multicenter, randomized controlled trial, was performed. Pati…

Rank96.0

Systematic review or meta-analysis

Orgasm-associated urinary incontinence (climacturia) after radical prostatectomy: current concepts in pathophysiology and management.

Sexual medicine reviews · 2026 · PMID 42823064

INTRODUCTION: Radical prostatectomy (RP) for prostate cancer commonly results in sexual dysfunction and stress urinary incontinence, including climacturia-orgasm-associated urinary incontinence. Prevalence estimates range widely (20%-93%, averaging closer to 30%), and the condition is likely underreported despite its substantial psychosocial impact, including embarrassment, relationship strain, and avoidance of sexual activity. This review summarizes its pathophysiology, prevalence, and management following RP. MET…

Rank96.0

Systematic review or meta-analysis

Burden of Treatment-Induced Vasomotor Symptoms in Men With Prostate Cancer on Androgen-Deprivation Therapy: A Systematic Literature Review.

Prostate cancer · 2026 · PMID 42724429

BACKGROUND: Androgen-deprivation therapy (ADT) for prostate cancer (PCa) is associated with vasomotor symptoms (VMS; hot flashes and night sweats). However, the impact of VMS has not been well characterized. This systematic literature review analyzed patient-reported outcome (PRO) instruments used to assess the quality of life (QoL) impact of ADT-induced VMS as well as the associated humanistic burden and epidemiology. METHODS: MEDLINE In-Progress, Embase, Cochrane Database of Systematic Reviews (2011-2024), and ma…

Rank95.0

Randomized controlled trial

Safety and patient-reported outcomes of multimodal PSMA PET/MRI-guided prostate biopsy: results from the prospective multicenter DEPROMP trial.

World journal of urology · 2026 · PMID 42752988

Rank92.8

Randomized clinical studyResult signal: harm

Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial.

Clinical and translational radiation oncology · 2026 · PMID 42741462

BACKGROUND AND PURPOSE: Moderate hypofractionation is increasingly used in salvage radiotherapy (SRT) after radical prostatectomy, although prospective data in the postoperative setting remain limited. We evaluated early adverse events and patient-reported outcomes (PROs) according to fractionation schedule within a prospective multicenter phase III trial. MATERIALS AND METHODS: This prespecified interim analysis included the first 250 patients enrolled in the URONCOR 06-24 randomized trial (NCT05781217). SRT was d…

Rank92.6

Randomized clinical study

Ultrahypofractionated linac-based radiotherapy of primary prostate cancer - early results of an Austrian nationwide registry study.

Clinical and translational radiation oncology · 2026 · PMID 42621857

BACKGROUND AND PURPOSE: Ultrahypofractionated radiotherapy (UHFX) has emerged as an attractive alternative to normo- and moderately hypofractionated regimens for localized prostate cancer. However, its broader adoption remains limited by technical challenges and concerns regarding genitourinary toxicity. We established a nationwide Austrian registry of low and intermediate risk localized prostate cancer patients treated with linac-based stereotactic body radiation therapy (SBRT) to provide real-world data about UHF…

Rank92.0

Randomized controlled trial

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42595485

Randomized Controlled Trials60 records

Rank109.2

Systematic review or meta-analysisResult signal: null

Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis.

International urology and nephrology · 2026 · PMID 42230439

Rank107.4

Systematic review or meta-analysisResult signal: null

Whole-pelvic Versus Prostate-only Radiotherapy in Clinically Node-negative High-Risk Localised Prostate Cancer: A Systematic Review and Meta-analysis with Reconstructed Individual-patient Data.

Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026 · PMID 42727425

Rank106.7

Systematic review or meta-analysis

PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis.

Clinical genitourinary cancer · 2026 · PMID 42586923

Rank106.0

Systematic review or meta-analysis

Artificial intelligence in genitourinary oncology: publication trends and systematic review.

BJU international · 2026 · PMID 42360093

OBJECTIVE: To conduct an analysis of publication trends and a systematic review of randomized controlled trials (RCTs) to characterize the current state of artificial intelligence (AI) use in genitourinary (GU) oncology, as AI has emerged as a transformative tool in healthcare with potential applications in diagnostics, treatment planning, and prognostication. METHODS: We searched the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE; Ovid), and Cumulative Index to …

Rank101.0

Systematic review or meta-analysis

Exercise During Active Surveillance for Localized Low-Risk Prostate Cancer: Current Evidence and a Survivorship Framework.

Current oncology (Toronto, Ont.) · 2026 · PMID 42930166

Urology practice · 2026 · PMID 42268725

INTRODUCTION: Cost analyses serve to inform evidence-based decisions for health care utilization while balancing clinical outcomes. Randomized studies have demonstrated minimal differences between transrectal biopsy (TR-Bx) and transperineal prostate biopsy (TP-Bx) for cancer detection and complications. Here, we present a comprehensive analysis of costs associated with TR-Bx and TP-Bx and related health care utilization from the ProBE-PC study. METHODS: A total of 718 men completed a randomly assigned TR-Bx or TP-…

Rank97.0

Randomized controlled trialResult signal: null

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532646

Rank96.4

Randomized controlled trial

Frozen section analysis assisted MRI targeted prostate biopsy - results of the randomized clinical FAST trial.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42858622

PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) targeted prostate biopsy is still commonly combined with systematic biopsy, resulting in a high number of extracted biopsy cores. This study evaluated whether a frozen section analysis (FSA) guided biopsy strategy enabling immediate assessment of targeted biopsy and omitting systematic biopsy in case of clinically significant prostate cancer (csPCa) is non-inferior to standard combined biopsy while substantially reducing the number of biopsy cores. MATERIA…

Rank96.4

Randomized controlled trialResult signal: harm

Quality of Life After Postprostatectomy Radiotherapy: A TROG 08.03 RAVES Randomized Controlled Trial Substudy.

European urology oncology · 2026 · PMID 42425869

BACKGROUND AND OBJECTIVE: There is continued uncertainty about whether the timing of radiotherapy (RT) after radical prostatectomy (RP) affects toxicity. This study assesses differences in patient-reported quality of life (QOL) for patients randomized to adjuvant RT (aRT) or salvage RT (sRT) after RP. METHODS: This is a planned secondary analysis of a randomized trial comparing aRT with sRT delivered if prostate-specific antigen increased to >0.2 ng/ml. QOL was measured using the EORTC (European Organization for Re…

Rank96.4

Randomized controlled trial

Comparison of local anesthesia techniques for pain control during transrectal ultrasound-guided prostate biopsy: A prospective randomized study.

The French journal of urology · 2026 · PMID 42471126

Rank96.3

Randomized controlled trial

Opioid-free versus opioid-based anesthesia for robot-assisted radical prostatectomy: a single-center randomized controlled trial.

Journal of robotic surgery · 2026 · PMID 42867736

Multimodal, opioid-sparing analgesia is standard in urological surgery, and there is additional interest in eliminating intraoperative opioids in prostate cancer surgery. Randomized evidence for opioid-free anesthesia (OFA) in robot-assisted radical prostatectomy (RARP) is lacking. In this single-center randomized controlled trial, adult men undergoing RARP were allocated 1:1 to OFA (dexmedetomidine plus ketamine, no intraoperative opioids) or a remifentanil-based technique. Both groups received identical multimoda…

Rank96.2

Randomized controlled trial

Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort.

European urology oncology · 2026 · PMID 42697825

BACKGROUND AND OBJECTIVE: The Retzius-sparing (RS) robot-assisted radical prostatectomy (RARP) was proposed in 2010 to enhance early postoperative continence recovery. However, long-term oncological outcomes following this approach remain insufficiently characterized. This study reports the long-term oncological outcomes of a randomized controlled trial originally designed to compare early continence recovery in patients treated using the RS versus standard (anterior) approach. DESIGN, SETTING, PARTICIPATNS AND INT…

Rank96.0

Randomized controlled trialResult signal: null

Impact of a dietary and exercise intervention on health-related quality of life of prostate cancer patients on active surveillance with overweight/obesity: a secondary analysis of a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42862393

PURPOSE: Quality of life (QOL) is important for men on active surveillance (AS) for prostate cancer (PCa). To improve QOL, interventions such as those focused on diet and exercise have been proposed. However, their effectiveness remains unclear, especially in individuals with overweight/obesity. METHODS: We previously conducted and published a randomized controlled trial of a lifestyle intervention for PCa patients on AS with overweight/obesity. Men were randomized to as follows: (1) 6-month diet and exercise inter…

Rank95.0

Randomized controlled trial

Time-restricted eating to entrain circadian rhythms, increase physiological responsiveness, and prevent stressor-induced frailty: A pilot randomized controlled trial.

Journal of geriatric oncology · 2026 · PMID 42570448

INTRODUCTION: Treatments for advanced and metastatic cancer can cause fatigue and accelerate the progression to frailty, a condition that increases vulnerabilities to stressors. Time-restricted eating (TRE) entails consuming food within a defined time window every day. TRE may help strengthen circadian rhythms and improve physiology. We present findings from a pilot study assessing the feasibility of TRE, when aligned with the daytime hours, as well as measures of fatigue, frailty, diurnal rhythms, and physiologica…

Rank95.0

Randomized controlled trial

Ablative radiotherapy in castration-resistant prostate cancer.

BJU international · 2026 · PMID 42389925

Rank94.1

Randomized controlled trial

Feasibility and safety of an exercise-based prehabilitation intervention before cancer surgery: a pilot randomised controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42905213

PURPOSE: The study aimed to assess the feasibility and safety of an exercise-based prehabilitation intervention and explore preliminary clinical outcomes in breast, colorectal, and prostate cancer patients awaiting surgery in a large regional healthcare service. METHODS: Patients with breast, prostate, or colorectal cancer scheduled for surgery were recruited at a single study centre and randomised (1:1) to prehabilitation or usual care. The intervention involved supervised aerobic exercise training 2-3 days per we…

Safety And Adverse Effects142 records

Rank108.4

Systematic review or meta-analysisResult signal: harm

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Prostate cancer and prostatic diseases · 2026 · PMID 41582208

Rank106.7

Systematic review or meta-analysis

PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis.

Clinical genitourinary cancer · 2026 · PMID 42586923

Rank106.4

Systematic review or meta-analysis

The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.

Human vaccines & immunotherapeutics · 2026 · PMID 41672480

Rank106.2

Systematic review or meta-analysisResult signal: null

Effectiveness of Enhanced Recovery After Surgery Protocols for Robot Assisted Radical Prostatectomy: A Systematic Review and Meta-Analysis.

Journal of laparoendoscopic & advanced surgical techniques. Part A · 2026 · PMID 42421337

BACKGROUND: Enhanced recovery after surgery (ERAS) protocols aim to improve perioperative outcomes through evidence-based, multimodal care pathways. While ERAS is well established in radical cystectomy, its role in robotic-assisted radical prostatectomy (RARP) remains less clearly defined. This systematic review and meta-analysis evaluates the safety and efficacy of ERAS protocols in patients undergoing RARP. METHODS: A systematic search of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials was …

Rank102.9

Systematic review or meta-analysis

Prediction models for adverse events from prostate cancer curative radiotherapy: a systematic review of methodological quality.

Translational oncology · 2026 · PMID 42570550

BACKGROUND: Predicting risks of urinary, bowel, sexual, and other adverse effects following prostate cancer curative radiotherapy (PCa-RT) is essential for treatment personalization and patient counseling. Several clinical prediction models (CPMs) have been published; however, their methodological quality remains unclear. METHODS: We systematically reviewed studies developing or validating CPMs for adverse events after PCa-RT. Embase and Medline were searched for CPM studies for patient- or clinician-reported outco…

Rank102.7

Systematic review or meta-analysis

Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.

Effects on patient activation of eHealth support in addition to standard care in patients after radical prostatectomy: Analysis of secondary outcome from a randomized controlled trial.

PloS one · 2024 · PMID 39255260

INTRODUCTION: Prostate cancer is often treated with radical prostatectomy, but surgery can leave patients with side effects. Patients who actively take part in their rehabilitation have been shown to achieve better clinical outcomes. eHealth support has the potential to increase patient activation, but has rarely been evaluated in long-term randomized controlled trials. Therefore, we evaluated the effects on patient activation of eHealth support (electronic Patient Activation in Treatment at Home, ePATH) based on m…

Rank98.1

Randomized controlled trial

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42250604

Rank97.0

Randomized controlled trialResult signal: null

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532646

Rank96.0

Systematic review or meta-analysis

Clinical utility of endorectal balloons in prostate cancer external beam radiotherapy: a systematic review and meta-analysis.

Radiation oncology journal · 2026 · PMID 42810974

PURPOSE: This study aimed to systematically evaluate the clinical utility of endorectal balloons (ERB) for motion management and organ-at-risk sparing in prostate cancer patients receiving external beam radiotherapy (EBRT) or stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: A systematic search was conducted in Ovid MEDLINE, Embase, the Cochrane Library, and Korean databases through May 8, 2024. Primary outcomes included safety, toxicity, prostate motion, and dosimetric parameters. The risk of bias was …

Rank96.0

Systematic review or meta-analysis

Orgasm-associated urinary incontinence (climacturia) after radical prostatectomy: current concepts in pathophysiology and management.

Sexual medicine reviews · 2026 · PMID 42823064

Treatments That Failed Clinical Trials64 records

Rank99.7

Randomized controlled trial

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

The Lancet. Oncology · 2026 · PMID 42061373

BACKGROUND: Serum prostate-specific antigen (PSA) concentrations decrease after hormone therapy for prostate cancer, with the nadir serving as a potentially useful prognostic biomarker. To support clinical use, we evaluated the association between PSA nadir values and survival outcomes, stratified by pre-treatment metastatic volume or, in patients with non-metastatic cancer, stratified by lymph node status. METHODS: As part of the STAMPEDE platform trial, patients with metastatic or very high-risk non-metastatic pr…

Rank99.7

Randomized controlled trialResult signal: mixed

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

JAMA · 2026 · PMID 42593775

Rank99.7

Randomized controlled trialResult signal: benefit

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

The Lancet. Oncology · 2026 · PMID 42697217

Rank99.3

Randomized controlled trialResult signal: null

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42161369

OBJECTIVES: The ENABLE study, an investigator-initiated, multicenter, randomized controlled trial, demonstrated comparable survival benefits between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) for castration-resistant prostate cancer (CRPC). Because randomized controlled trials typically exclude patients with a history of other cancers (HOCs), we evaluated the efficacy of these agents in this population. METHODS: This sub-analysis was conducted as a post hoc analysis using data from the ENABLE study.…

Rank99.2

Randomized controlled trial

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

European urology · 2026 · PMID 41833492

Rank99.1

Randomized controlled trialResult signal: null

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

European urology oncology · 2026 · PMID 41033927

BACKGROUND AND OBJECTIVE: Whether cabazitaxel or an androgen receptor pathway inhibitor (ARPI) is the optimal treatment option for poor-prognosis metastatic castration-resistant prostate cancer (mCRPC), progressing on docetaxel, remains unclear. There are limited prospective data supporting a preference for one of these treatments and few candidate biomarkers to inform individual patient management. This study aims to compare the clinical efficacy of cabazitaxel versus ARPIs in patients with poor-prognosis mCRPC wh…

Rank98.9

Randomized controlled trialResult signal: null

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Clinical genitourinary cancer · 2026 · PMID 42509097

Rank98.9

Randomized controlled trialResult signal: null

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

The Prostate · 2026 · PMID 42391446

BACKGROUND: This study aimed to clarify whether variations in the lowest prostate‑specific antigen (PSA) level prior to the development of castration‑resistant prostate cancer (CRPC) influence the efficacy of subsequent enzalutamide (ENZ) or abiraterone plus prednisolone (ABI) therapy in metastatic CRPC. METHODS: Using data from the ENABLE study, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on the lowest PSA level prior to metas…

Rank98.6

Randomized controlled trialResult signal: null

The effect of povidone-iodine-enhanced rectal enema on procedure-related infectious complications before transrectal ultrasound-guided prostate biopsy: A prospective randomized study.

Medicine · 2026 · PMID 42152336

BACKGROUND: To prospectively evaluate the effects of rectal cleansing using a povidone-iodine (PI) and PI enhanced rectal enema on procedure-related infectious complications in patients undergoing transrectal prostate biopsy. METHODS: Between September 2023 and March 2024, patients scheduled for their first transrectal ultrasound-guided prostate biopsy due to elevated prostate-specific antigen levels, suspicious multiparametric prostate magnetic resonance imaging findings, or abnormal digital rectal examination wer…

Rank98.6

Randomized controlled trial

Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility.

Scandinavian journal of urology · 2026 · PMID 41778764

OBJECTIVE: This study aimed to compare test sensitivity for detecting aggressive prostate cancer and test specificity (measured by reduction in prostate biopsies) between algorithm-triage and standard systematic biopsy in elderly men with suspected prostate cancer. METHODS: This randomised controlled trial enrolled men ≥ 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, int…

Rank98.6

Randomized controlled trialResult signal: null

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

European urology oncology · 2026 · PMID 41862335

Rank98.5

Randomized controlled trialResult signal: null

Effects on patient activation of eHealth support in addition to standard care in patients after radical prostatectomy: Analysis of secondary outcome from a randomized controlled trial.

PloS one · 2024 · PMID 39255260

Rank98.4

Randomized controlled trial

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.

BJU international · 2026 · PMID 41896701

OBJECTIVES: To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform-positive and -negative prostate cancer (PCa) and the 15-year risk of metastasis or death from PCa in patients who underwent radical prostatectomy (RP). PATIENTS AND METHODS: Between 1999 and 2009, the ProtecT phase 3 clinical trial enrolled 1643 men with clinically localised PCa who were randomised to receive a…

Rank98.2

Randomized controlled trialResult signal: benefit

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42378957

BACKGROUND: Patients with metastatic hormone-sensitive prostate cancer (mHSPC) require long-term treatment to delay progression and improve survival, while minimizing adverse events or negative impact on symptoms (e.g. pain) and health-related quality of life (HRQoL). In ARASENS (NCT02799602), darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (primary endpoint) versus placebo plus ADT and docetaxel. We report clinically relevant endpoints and HRQoL in ARASENS…

Rank98.2

Randomized controlled trial

Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis.

Contemporary clinical trials · 2026 · PMID 42476253

BACKGROUND: Micro-ultrasound (microUS) represents a potential alternative to multiparametric magnetic resonance (mpMRI) in guiding prostate biopsy, with level 1 evidence demonstrating non-inferiority to detect Grade Group ≥2 (GG ≥ 2) prostate cancer in biopsy-naïve men. However, a critical gap remains in the screening pathway, in which imaging is needed to identify men at risk and determine whether biopsy is warranted. METHODS: MUSIC-Screen is a phase 3, open-label, noninferiority 1:1 randomized controlled trial ev…

Rank98.2

Randomized controlled trialResult signal: mixed

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Cancer · 2026 · PMID 42319132

BACKGROUND: The combination of olaparib plus radium-223 improved progression-free survival in patients with metastatic castration-resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient-reported outcome (PRO) analysis of this trial is reported. METHODS: Patients were randomized 1:1 to olaparib plus radium-223 (arm A) or radium-223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and …

Rank98.1

Randomized controlled trial

European urology · 2026 · PMID 41494929

We report long-term outcomes from the phase 3 SAKK 09/10 trial that randomly assigned men with biochemical progression after radical prostatectomy to conventional-dose (64 Gy) or dose-intensified (70 Gy) salvage radiotherapy (SRT) to the prostate bed without hormonal therapy. The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), and late toxicity. Between February 2011 and April …

Rank97.0

Randomized controlled trialResult signal: null

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532646

Rank97.0

Randomized controlled trial

Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.

European urology oncology · 2026 · PMID 39613566

BACKGROUND AND OBJECTIVE: There is uncertainty regarding the clinical significance of 68Ga-PSMA-11 positron emission tomography (PET) computed tomography (CT) findings in men with prostate cancer. In this prespecified objective of the proPSMA study, we report the prognostic value of PET-defined nodal involvement. METHODS: Men with intermediate- to high-risk prostate cancer (grade group 3-5, prostate-specific antigen [PSA] ≥20 ng/ml, or clinical stage ≥T3) underwent 68Ga-PSMA-11 PET-CT or CT and bone scanning as fir…

Research information notice

Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.